0001831097 December 31 2025 Q2 false http://fasb.org/us-gaap/2025#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2025#OtherLiabilitiesNoncurrent xbrli:shares iso4217:USD iso4217:USD xbrli:shares agl:member xbrli:pure agl:lawsuit agl:entity agl:investment agl:partner agl:geography 0001831097 2025-01-01 2025-06-30 0001831097 2025-07-31 0001831097 2025-06-30 0001831097 2024-12-31 0001831097 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2025-06-30 0001831097 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2024-12-31 0001831097 agl:MedicalServicesMember 2025-04-01 2025-06-30 0001831097 agl:MedicalServicesMember 2024-04-01 2024-06-30 0001831097 agl:MedicalServicesMember 2025-01-01 2025-06-30 0001831097 agl:MedicalServicesMember 2024-01-01 2024-06-30 0001831097 agl:OtherOperatingMember 2025-04-01 2025-06-30 0001831097 agl:OtherOperatingMember 2024-04-01 2024-06-30 0001831097 agl:OtherOperatingMember 2025-01-01 2025-06-30 0001831097 agl:OtherOperatingMember 2024-01-01 2024-06-30 0001831097 2025-04-01 2025-06-30 0001831097 2024-04-01 2024-06-30 0001831097 2024-01-01 2024-06-30 0001831097 us-gaap:CommonStockMember 2025-03-31 0001831097 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001831097 us-gaap:RetainedEarningsMember 2025-03-31 0001831097 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001831097 2025-03-31 0001831097 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001831097 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2025-06-30 0001831097 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001831097 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001831097 us-gaap:CommonStockMember 2025-06-30 0001831097 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001831097 us-gaap:RetainedEarningsMember 2025-06-30 0001831097 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0001831097 us-gaap:CommonStockMember 2024-03-31 0001831097 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001831097 us-gaap:RetainedEarningsMember 2024-03-31 0001831097 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001831097 us-gaap:NoncontrollingInterestMember 2024-03-31 0001831097 2024-03-31 0001831097 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001831097 us-gaap:NoncontrollingInterestMember 2024-04-01 2024-06-30 0001831097 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001831097 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001831097 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001831097 us-gaap:CommonStockMember 2024-06-30 0001831097 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001831097 us-gaap:RetainedEarningsMember 2024-06-30 0001831097 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001831097 us-gaap:NoncontrollingInterestMember 2024-06-30 0001831097 2024-06-30 0001831097 us-gaap:CommonStockMember 2024-12-31 0001831097 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001831097 us-gaap:RetainedEarningsMember 2024-12-31 0001831097 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001831097 us-gaap:RetainedEarningsMember 2025-01-01 2025-06-30 0001831097 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-06-30 0001831097 us-gaap:CommonStockMember 2025-01-01 2025-06-30 0001831097 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-06-30 0001831097 us-gaap:CommonStockMember 2023-12-31 0001831097 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001831097 us-gaap:RetainedEarningsMember 2023-12-31 0001831097 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001831097 us-gaap:NoncontrollingInterestMember 2023-12-31 0001831097 2023-12-31 0001831097 us-gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0001831097 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-06-30 0001831097 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-06-30 0001831097 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001831097 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0001831097 agl:PlatformSupportCostsMember agl:ReportableSegmentMember 2025-04-01 2025-06-30 0001831097 agl:PlatformSupportCostsMember agl:ReportableSegmentMember 2024-04-01 2024-06-30 0001831097 agl:ReportableSegmentMember 2025-04-01 2025-06-30 0001831097 agl:ReportableSegmentMember 2024-04-01 2024-06-30 0001831097 agl:PlatformSupportCostsMember agl:ReportableSegmentMember 2025-01-01 2025-06-30 0001831097 agl:PlatformSupportCostsMember agl:ReportableSegmentMember 2024-01-01 2024-06-30 0001831097 agl:ReportableSegmentMember 2025-01-01 2025-06-30 0001831097 agl:ReportableSegmentMember 2024-01-01 2024-06-30 0001831097 agl:PayorAMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-04-01 2025-06-30 0001831097 agl:PayorAMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2024-04-01 2024-06-30 0001831097 agl:PayorAMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-06-30 0001831097 agl:PayorAMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2024-01-01 2024-06-30 0001831097 agl:PayorBMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-04-01 2025-06-30 0001831097 agl:PayorBMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2024-04-01 2024-06-30 0001831097 agl:PayorBMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-06-30 0001831097 agl:PayorBMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2024-01-01 2024-06-30 0001831097 agl:PayorCMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-04-01 2025-06-30 0001831097 agl:PayorCMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-06-30 0001831097 agl:PayorDMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-04-01 2025-06-30 0001831097 agl:PayorEMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-04-01 2025-06-30 0001831097 agl:PayorEMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-06-30 0001831097 agl:PayorBMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2024-01-01 2024-12-31 0001831097 agl:PayorCMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2025-01-01 2025-06-30 0001831097 agl:PayorCMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2024-01-01 2024-12-31 0001831097 agl:PayorDMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2025-01-01 2025-06-30 0001831097 agl:PayorDMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2024-01-01 2024-12-31 0001831097 agl:PayorEMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2025-01-01 2025-06-30 0001831097 agl:PayorEMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2024-01-01 2024-12-31 0001831097 us-gaap:CorporateDebtSecuritiesMember 2025-06-30 0001831097 us-gaap:CorporateDebtSecuritiesMember 2024-12-31 0001831097 us-gaap:USTreasurySecuritiesMember 2025-06-30 0001831097 us-gaap:USTreasurySecuritiesMember 2024-12-31 0001831097 us-gaap:DebtSecuritiesMember 2025-04-01 2025-06-30 0001831097 us-gaap:CashAndCashEquivalentsMember 2025-04-01 2025-06-30 0001831097 us-gaap:DebtSecuritiesMember 2024-04-01 2024-06-30 0001831097 us-gaap:CashAndCashEquivalentsMember 2024-04-01 2024-06-30 0001831097 us-gaap:DebtSecuritiesMember 2025-01-01 2025-06-30 0001831097 us-gaap:CashAndCashEquivalentsMember 2025-01-01 2025-06-30 0001831097 us-gaap:DebtSecuritiesMember 2024-01-01 2024-06-30 0001831097 us-gaap:CashAndCashEquivalentsMember 2024-01-01 2024-06-30 0001831097 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member 2025-06-30 0001831097 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2025-06-30 0001831097 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member 2025-06-30 0001831097 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member 2024-12-31 0001831097 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2024-12-31 0001831097 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member 2024-12-31 0001831097 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member 2025-06-30 0001831097 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2025-06-30 0001831097 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member 2025-06-30 0001831097 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member 2024-12-31 0001831097 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2024-12-31 0001831097 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member 2024-12-31 0001831097 us-gaap:FairValueInputsLevel1Member 2025-06-30 0001831097 us-gaap:FairValueInputsLevel2Member 2025-06-30 0001831097 us-gaap:FairValueInputsLevel3Member 2025-06-30 0001831097 us-gaap:FairValueInputsLevel1Member 2024-12-31 0001831097 us-gaap:FairValueInputsLevel2Member 2024-12-31 0001831097 us-gaap:FairValueInputsLevel3Member 2024-12-31 0001831097 us-gaap:UnassertedClaimMember 2025-06-30 0001831097 us-gaap:UnassertedClaimMember 2024-12-31 0001831097 agl:SecuredTermLoanFacilityMember 2021-02-18 0001831097 agl:SecuredRevolvingFacilityMember 2021-02-18 0001831097 us-gaap:StandbyLettersOfCreditMember 2021-02-18 0001831097 agl:SecuredTermLoanFacilityMember 2021-02-18 2021-02-18 0001831097 agl:SecuredTermLoanFacilityMember 2025-06-30 0001831097 agl:SecuredRevolvingFacilityMember 2025-06-30 0001831097 us-gaap:StandbyLettersOfCreditMember 2025-06-30 0001831097 us-gaap:StandbyLettersOfCreditMember 2025-01-01 2025-06-30 0001831097 agl:SecuredTermLoanFacilityMember us-gaap:SecuredOvernightFinancingRateSofrMember srt:MaximumMember 2023-05-25 2023-05-25 0001831097 agl:SecuredTermLoanFacilityMember us-gaap:SecuredOvernightFinancingRateSofrMember srt:MinimumMember 2023-05-25 2023-05-25 0001831097 agl:SecuredTermLoanFacilityMember us-gaap:BaseRateMember srt:MaximumMember 2023-05-25 2023-05-25 0001831097 agl:SecuredTermLoanFacilityMember us-gaap:FederalFundsEffectiveSwapRateMember 2023-05-25 2023-05-25 0001831097 agl:SecuredTermLoanFacilityMember us-gaap:SecuredOvernightFinancingRateSofrMember 2023-05-25 2023-05-25 0001831097 agl:SecuredTermLoanFacilityMember us-gaap:BaseRateMember srt:MinimumMember 2023-05-25 2023-05-25 0001831097 agl:SecuredRevolvingFacilityMember srt:MinimumMember 2023-05-25 2023-05-25 0001831097 agl:ConsolidatedSecuritiesMatterMember 2024-02-01 2024-03-31 0001831097 agl:DerivativeMattersMember 2024-05-01 2024-10-31 0001831097 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-06-30 0001831097 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001831097 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-06-30 0001831097 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001831097 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember 2025-06-30 0001831097 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2025-01-01 2025-06-30 0001831097 us-gaap:SuretyBondMember us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember 2025-06-30 0001831097 us-gaap:SuretyBondMember us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember 2024-12-31 0001831097 agl:OtherEquityMethodInvestmentsMember 2025-06-30 0001831097 agl:OtherEquityMethodInvestmentsMember 2024-12-31 0001831097 agl:ACOREACHMember 2025-06-30 0001831097 agl:ACOREACHMember 2024-12-31 0001831097 agl:MedicalServicesMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2025-04-01 2025-06-30 0001831097 agl:MedicalServicesMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2024-04-01 2024-06-30 0001831097 agl:MedicalServicesMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2025-01-01 2025-06-30 0001831097 agl:MedicalServicesMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2024-01-01 2024-06-30 0001831097 agl:OtherOperatingMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2025-04-01 2025-06-30 0001831097 agl:OtherOperatingMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2024-04-01 2024-06-30 0001831097 agl:OtherOperatingMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2025-01-01 2025-06-30 0001831097 agl:OtherOperatingMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2024-01-01 2024-06-30 0001831097 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2025-04-01 2025-06-30 0001831097 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2024-04-01 2024-06-30 0001831097 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2025-01-01 2025-06-30 0001831097 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2024-01-01 2024-06-30 0001831097 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2025-06-30 0001831097 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2024-12-31 0001831097 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2025-01-01 2025-06-30 0001831097 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2024-01-01 2024-06-30
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________________________________________
FORM 10-Q
_______________________________________________________
(Mark One)

x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended June 30, 2025
OR

o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to
Commission file number 001-40332
_______________________________________________________
agilon health, inc.
(Exact name of registrant as specified in its charter)

Delaware | 37-1915147
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.)

440 Polaris Parkway, Suite 550
Westerville, Ohio 43082
(Address of principal executive offices)
(562) 256-3800
(Registrant’s telephone number, including area code)
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading symbol(s) | Name of each exchange on which registered
Common stock, $0.01 par value | AGL | New York Stock Exchange

_______________________________________________________
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x NO o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer | x |  | Accelerated Filer | o
Non-accelerated Filer | o |  | Smaller Reporting Company | o
|  |  | Emerging Growth Company | o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) YES o NO x
At July 31, 2025, there were 414,423,149 shares of the registrant’s $0.01 par value common stock outstanding.

Table of Contents
agilon health, inc.
INDEX

PART I. FINANCIAL INFORMATION |
Item 1. | Financial Statements: |
| Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 | 3
| Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2025 and 2024 | 4
| Condensed Consolidated Statements of Comprehensive Income (Loss) for the Three and Six Months Ended June 30, 2025 and 2024 | 5
| Condensed Consolidated Statements of Stockholders’ Equity (Deficit) for the Three and Six Months Ended June 30, 2025 and 2024 | 6
| Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024 | 8
| Notes to the Condensed Consolidated Financial Statements | 9
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 22
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 38
Item 4. | Controls and Procedures | 38
PART II. OTHER INFORMATION |
Item 1. | Legal Proceedings | 39
Item 1A. | Risk Factors | 39
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 39
Item 5. | Other Information | 39
Item 6. | Exhibits | 40
Signatures | 41

2

Table of Contents
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
agilon health, inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except per share data)

| June 30, 2025 |  | December 31, 2024
| (unaudited) |  |
ASSETS |  |  |
Current assets: |  |  |
Cash and cash equivalents | $ | 171,416 |  |  | $ | 188,231 |
Restricted cash and equivalents | — |  |  | 5,629 |
Marketable securities | 155,585 |  |  | 211,737 |
Receivables, net | 1,047,164 |  |  | 1,017,040 |
Prepaid expenses and other current assets, net | 78,495 |  |  | 35,137 |
Total current assets | 1,452,660 |  |  | 1,457,774 |
Property and equipment, net | 27,410 |  |  | 28,169 |
Intangible assets, net | 65,595 |  |  | 72,771 |
Goodwill | 24,133 |  |  | 24,133 |
Other assets | 143,097 |  |  | 151,136 |
Total assets | $ | 1,712,895 |  |  | $ | 1,733,983 |
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) |  |  |
Current liabilities: |  |  |
Medical claims and related payables | $ | 1,042,257 |  |  | $ | 931,664 |
Accounts payable and accrued expenses | 171,886 |  |  | 220,342 |
Current debt | 34,945 |  |  | — |
Total current liabilities | 1,249,088 |  |  | 1,152,006 |
Long-term debt | — |  |  | 34,904 |
Other liabilities | 54,878 |  |  | 76,121 |
Total liabilities | 1,303,966 |  |  | 1,263,031 |
Commitments and contingencies |  |  |
Stockholders' equity (deficit): |  |  |
Common stock, $0.01 par value: 2,000,000 shares authorized; 414,283 and 412,194 shares issued and outstanding, respectively | 4,143 |  |  | 4,122 |
Additional paid-in capital | 2,083,234 |  |  | 2,053,895 |
Accumulated deficit | (1,679,235) |  |  | (1,586,977) |
Accumulated other comprehensive income (loss) | 787 |  |  | (88) |
Total stockholders’ equity (deficit) | 408,929 |  |  | 470,952 |
Total liabilities and stockholders’ equity (deficit) | $ | 1,712,895 |  |  | $ | 1,733,983 |

The condensed consolidated balance sheets include assets and liabilities of consolidated variable interest entities (“VIEs”) as agilon health, inc., together with its consolidated subsidiaries and VIEs (the “Company”), is the primary beneficiary of these VIEs. The condensed consolidated balance sheets include total assets that can only be used to settle obligations of the Company’s consolidated VIEs totaling $1.19 billion and $1.17 billion as of June 30, 2025 and December 31, 2024, respectively, and total liabilities of the Company’s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $1.20 billion and $1.13 billion as of June 30, 2025 and December 31, 2024, respectively. See Note 14 for additional details.
See accompanying Notes to the Condensed Consolidated Financial Statements.
3

Table of Contents
agilon health, inc.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(unaudited)

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Revenues: |  |  |  |  |  |  |
Medical services revenue | $ | 1,392,039 |  |  | $ | 1,479,579 |  |  | $ | 2,921,918 |  |  | $ | 3,080,774 |
Other operating revenue | 2,943 |  |  | 3,179 |  |  | 5,846 |  |  | 6,338 |
Total revenues | 1,394,982 |  |  | 1,482,758 |  |  | 2,927,764 |  |  | 3,087,112 |
Expenses: |  |  |  |  |  |  |
Medical services expense | 1,445,245 |  |  | 1,374,060 |  |  | 2,847,112 |  |  | 2,817,902 |
Other medical expenses | 2,164 |  |  | 76,523 |  |  | 82,357 |  |  | 161,947 |
General and administrative | 56,281 |  |  | 69,612 |  |  | 122,237 |  |  | 146,034 |
Depreciation and amortization | 7,319 |  |  | 5,907 |  |  | 14,195 |  |  | 11,751 |
Total expenses | 1,511,009 |  |  | 1,526,102 |  |  | 3,065,901 |  |  | 3,137,634 |
Income (loss) from operations | (116,027) |  |  | (43,344) |  |  | (138,137) |  |  | (50,522) |
Other income (expense): |  |  |  |  |  |  |
Income (loss) from equity method investments | 5,412 |  |  | 9,955 |  |  | 18,084 |  |  | 15,639 |
Other income (expense), net | 7,879 |  |  | 4,841 |  |  | 17,140 |  |  | 10,733 |
Interest expense | (1,572) |  |  | (1,697) |  |  | (3,087) |  |  | (2,981) |
Income (loss) before income taxes | (104,308) |  |  | (30,245) |  |  | (106,000) |  |  | (27,131) |
Income tax benefit (expense) | (62) |  |  | (417) |  |  | (258) |  |  | (284) |
Income (loss) from continuing operations | (104,370) |  |  | (30,662) |  |  | (106,258) |  |  | (27,415) |
Discontinued operations: |  |  |  |  |  |  |
Income (loss) before gain (loss) on sales | — |  |  | — |  |  | — |  |  | (518) |
Adjustments on sale of assets, net | — |  |  | — |  |  | 14,000 |  |  | (8,763) |
Total discontinued operations | — |  |  | — |  |  | 14,000 |  |  | (9,281) |
Net income (loss) | (104,370) |  |  | (30,662) |  |  | (92,258) |  |  | (36,696) |
Noncontrolling interests’ share in (earnings) loss | — |  |  | (20) |  |  | — |  |  | (50) |
Net income (loss) attributable to common shares | $ | (104,370) |  |  | $ | (30,682) |  |  | $ | (92,258) |  |  | $ | (36,746) |
Net income (loss) per common share, basic and diluted |  |  |  |  |  |  |
Continuing operations | $ | (0.25) |  |  | $ | (0.07) |  |  | $ | (0.25) |  |  | $ | (0.07) |
Discontinued operations | $ | — |  |  | $ | — |  |  | $ | 0.03 |  |  | $ | (0.02) |
Weighted average shares outstanding |  |  |  |  |  |  |
Basic and diluted | 413,836 |  | 411,271 |  | 413,388 |  | 409,152

See accompanying Notes to the Condensed Consolidated Financial Statements.
4

Table of Contents
agilon health, inc.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(in thousands)
(unaudited)

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Net income (loss) | $ | (104,370) |  |  | $ | (30,662) |  |  | $ | (92,258) |  |  | $ | (36,696) |
Other comprehensive income (loss): |  |  |  |  |  |  |
Net unrealized gain (loss) on marketable securities, net of tax | 210 |  |  | 325 |  |  | 822 |  |  | (132) |
Foreign currency translation adjustment | 34 |  |  | (25) |  |  | 53 |  |  | (17) |
Total comprehensive income (loss) | (104,126) |  |  | (30,362) |  |  | (91,383) |  |  | (36,845) |
Comprehensive (income) loss attributable to noncontrolling interests | — |  |  | (20) |  |  | — |  |  | (50) |
Total comprehensive income (loss) attributable to agilon health, inc. | $ | (104,126) |  |  | $ | (30,382) |  |  | $ | (91,383) |  |  | $ | (36,895) |

See accompanying Notes to the Condensed Consolidated Financial Statements.
5

Table of Contents
agilon health, inc.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)
(in thousands)
(unaudited)
For the three months ended June 30, 2025:

| Total Stockholders’ Equity (Deficit)
| Common Stock |  | Additional Paid-In Capital |  | Accumulated Deficit |  | Accumulated Other Comprehensive Income (Loss) |  |  |  | Total Stockholders’ Equity (Deficit)
| Shares |  | Amount |  |  |  |  |
April 1, 2025 | 413,023 |  | $ | 4,130 |  |  | $ | 2,070,446 |  |  | $ | (1,574,865) |  |  | $ | 543 |  |  |  |  | $ | 500,254 |
Net income (loss) | — |  |  | — |  |  | — |  |  | (104,370) |  |  | — |  |  |  |  | (104,370) |
Other comprehensive income (loss) | — |  |  | — |  |  | — |  |  | — |  |  | 244 |  |  |  |  | 244 |
Exercise of stock options | 24 |  | — |  |  | 110 |  |  | — |  |  | — |  |  |  |  | 110 |
Vesting of restricted stock units | 1,733 |  | 18 |  |  | (18) |  |  | — |  |  | — |  |  |  |  | — |
Shares withheld related to net share settlement | (497) |  | (5) |  |  | (2,685) |  |  | — |  |  | — |  |  |  |  | (2,690) |
Stock-based compensation expense | — |  | — |  | 15,381 |  | — |  |  | — |  |  |  |  | 15,381
June 30, 2025 | 414,283 |  | $ | 4,143 |  |  | $ | 2,083,234 |  |  | $ | (1,679,235) |  |  | $ | 787 |  |  |  |  | $ | 408,929 |

For the three months ended June 30, 2024:

| Total Stockholders’ Equity (Deficit)
| Common Stock |  | Additional Paid-In Capital |  | Accumulated Deficit |  | Accumulated Other Comprehensive Income (Loss) |  | Noncontrolling Interests |  | Total Stockholders’ Equity (Deficit)
| Shares |  | Amount |  |  |  |  |
April 1, 2024 | 410,843 |  | $ | 4,108 |  |  | $ | 2,020,803 |  |  | $ | (1,332,890) |  |  | $ | (2,747) |  |  | $ | (788) |  |  | $ | 688,486 |
Net income (loss) | — |  |  | — |  |  | — |  |  | (30,682) |  |  | — |  |  | 20 |  |  | (30,662) |
Other comprehensive income (loss) | — |  |  | — |  |  | — |  |  | — |  |  | 300 |  |  | — |  |  | 300 |
Exercise of stock options | 42 |  | 1 |  |  | 170 |  |  | — |  |  | — |  |  | — |  |  | 171 |
Vesting of restricted stock units | 690 |  | 6 |  |  | (6) |  |  | — |  |  | — |  |  | — |  |  | — |
Shares withheld related to net share settlement | (128) |  | (1) |  |  | (634) |  |  | — |  |  | — |  |  | — |  |  | (635) |
Stock-based compensation expense | — |  | — |  |  | 18,207 |  |  | — |  |  | — |  |  | — |  |  | 18,207 |
June 30, 2024 | 411,447 |  | $ | 4,114 |  |  | $ | 2,038,540 |  |  | $ | (1,363,572) |  |  | $ | (2,447) |  |  | $ | (768) |  |  | $ | 675,867 |

6

Table of Contents
agilon health, inc.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)
(in thousands)
(unaudited)
For the six months ended June 30, 2025:

| Total Stockholders’ Equity (Deficit)
| Common Stock |  | Additional Paid-In Capital |  | Accumulated Deficit |  | Accumulated Other Comprehensive Income (Loss) |  | Total Stockholders’ Equity (Deficit)
| Shares |  | Amount |  |  |  |
January 1, 2025 | 412,194 |  | $ | 4,122 |  |  | $ | 2,053,895 |  |  | $ | (1,586,977) |  |  | $ | (88) |  |  | $ | 470,952 |
Net income (loss) | — |  | — |  |  | — |  |  | (92,258) |  |  | — |  |  | (92,258) |
Other comprehensive income (loss) | — |  | — |  |  | — |  |  | — |  |  | 875 |  |  | 875 |
Exercise of stock options | 24 |  |  | — |  |  | 110 |  |  | — |  |  | — |  |  | 110 |
Vesting of restricted stock units | 2,604 |  | 26 |  |  | (26) |  |  | — |  |  | — |  |  | — |
Shares withheld related to net share settlement | (539) |  | (5) |  |  | (2,846) |  |  | — |  |  | — |  |  | (2,851) |
Stock-based compensation expense | — |  | — |  |  | 32,101 |  |  | — |  |  | — |  |  | 32,101 |
June 30, 2025 | 414,283 |  | $ | 4,143 |  |  | $ | 2,083,234 |  |  | $ | (1,679,235) |  |  | $ | 787 |  |  | $ | 408,929 |

For the six months ended June 30, 2024:

| Total Stockholders’ Equity (Deficit)
| Common Stock |  | Additional Paid-In Capital |  | Accumulated Deficit |  | Accumulated Other Comprehensive Income (Loss) |  | Noncontrolling Interest |  | Total Stockholders’ Equity (Deficit)
| Shares |  | Amount |  |  |  |  |
January 1, 2024 | 406,387 |  | $ | 4,064 |  |  | $ | 1,986,899 |  |  | $ | (1,326,826) |  |  | $ | (2,298) |  |  | $ | (818) |  |  | $ | 661,021 |
Net income (loss) | — |  | — |  |  | — |  |  | (36,746) |  |  | — |  |  | 50 |  |  | (36,696) |
Other comprehensive income (loss) | — |  | — |  |  | — |  |  | — |  |  | (149) |  |  | — |  |  | (149) |
Exercise of stock options | 1,476 |  | 15 |  |  | 2,611 |  |  | — |  |  | — |  |  | — |  |  | 2,626 |
Vesting of restricted stock units | 1,860 |  | 17 |  |  | (17) |  |  | — |  |  | — |  |  | — |  |  | — |
Shares withheld related to net share settlement | (250) |  | (2) |  |  | (1,279) |  |  | — |  |  | — |  |  | — |  |  | (1,281) |
Issuance of common stock | 1,974 |  | 20 |  |  | 15,210 |  |  | — |  |  | — |  |  | — |  |  | 15,230 |
Stock-based compensation expense | — |  | — |  |  | 35,116 |  |  | — |  |  | — |  |  | — |  |  | 35,116 |
June 30, 2024 | 411,447 |  | $ | 4,114 |  |  | $ | 2,038,540 |  |  | $ | (1,363,572) |  |  | $ | (2,447) |  |  | $ | (768) |  |  | $ | 675,867 |

See accompanying Notes to the Condensed Consolidated Financial Statements.
7

Table of Contents
agilon health, inc.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)

| Six Months Ended June 30,
| 2025 |  | 2024
Cash flows from operating activities: |  |  |
Net income (loss) | $ | (92,258) |  |  | $ | (36,696) |
Adjustments to reconcile net income (loss) to net cash used in operating activities: |  |  |
Depreciation and amortization | 14,195 |  |  | 11,751 |
Stock-based compensation expense | 32,101 |  |  | 35,116 |
Loss (income) from equity method investments | (18,084) |  |  | (15,639) |
Distributions of earnings from equity method investments | — |  |  | 3,340 |
Adjustments on sale of assets, net | (14,000) |  |  | 3,784 |
Other noncash items | (3,107) |  |  | (837) |
Changes in operating assets and liabilities | 14,081 |  |  | (67,312) |
Net cash provided by (used in) operating activities | (67,072) |  |  | (66,493) |
Cash flows from investing activities: |  |  |
Purchase of property and equipment | (7,099) |  |  | (6,451) |
Purchase of intangible assets | (9,717) |  |  | (17,893) |
Investment in loans receivable and other | (1,000) |  |  | (9,742) |
Investments in marketable securities | (60,154) |  |  | (12,006) |
Proceeds from maturities of marketable securities and other | 125,339 |  |  | 115,747 |
Net cash provided by (used in) investing activities | 47,369 |  |  | 69,655 |
Cash flows from financing activities: |  |  |
Proceeds from (payments for) equity issuances, net | (2,741) |  |  | 1,345 |
Repayments of long-term debt | — |  |  | (2,500) |
Net cash provided by (used in) financing activities | (2,741) |  |  | (1,155) |
Net increase (decrease) in cash, cash equivalents and restricted cash and equivalents | (22,444) |  |  | 2,007 |
Cash, cash equivalents and restricted cash and equivalents, beginning of period | 193,860 |  |  | 114,329 |
Cash, cash equivalents and restricted cash and equivalents, end of period | $ | 171,416 |  |  | $ | 116,336 |

See accompanying Notes to the Condensed Consolidated Financial Statements.
8

Table of Contents
agilon health, inc.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

NOTE 1. Business

Description of Business
agilon health, inc., together with its consolidated subsidiaries and VIEs (the “Company”), through its partnerships and platform, provides the necessary capabilities, capital, and business model for existing physician groups to create a Medicare-centric, globally capitated line of business. As of June 30, 2025, the Company, through its contracted physician networks, provided care to approximately 497,500 Medicare Advantage members enrolled with private health plans. Additionally, the Company participates in the Centers for Medicare & Medicaid Services' (“CMS”) Accountable Care Organization Realizing Equity, Access, and Community Health (“ACO REACH”) Model and Medicare Shared Savings Program (“MSSP,” and together with ACO REACH, the “CMS ACO Models”) through its equity method investments.
See Note 14 for additional discussions related to the Company’s involvement with VIEs.
The Company’s largest shareholder is an investment fund associated with Clayton Dubilier & Rice, LLC (“CD&R”), a private equity firm. All funds affiliated with CD&R are considered related parties.

NOTE 2. Summary of Significant Accounting Policies

Basis of Presentation
The accompanying condensed consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The condensed consolidated financial statements include the accounts of agilon health, inc., its wholly-owned subsidiaries, and joint ventures and VIEs that it controls through voting rights or other means. Intercompany transactions and balances have been eliminated upon consolidation. All adjustments (consisting of normal recurring adjustments unless otherwise indicated), which the Company considers necessary to present fairly its financial position, results of operations, and cash flows, have been included. Operating results for the three and six months ended June 30, 2025 are not necessarily indicative of the results that may be expected for the year ending December 31, 2025. The accompanying condensed consolidated financial information should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2024 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission.
Use of Estimates
Management is required to make estimates and assumptions in the preparation of financial statements. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates can include, among other things, those used to determine revenues and related receivables from risk adjustments, medical services expense and related payables (including the reserve for incurred but not reported (“IBNR”) claims), and the valuation and related recognition of impairments of long-lived assets, including goodwill. Management’s estimates for revenue recognition, medical services expense, and other estimates, judgments, and assumptions, may be materially and adversely different from actual results. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates.
Property and Equipment
As of June 30, 2025 and December 31, 2024, the Company’s gross carrying amount of property and equipment was $58.6 million and $52.9 million, with accumulated depreciation of $31.2 million and $24.7 million, respectively. For the three months ended June 30, 2025 and 2024, the Company recognized $3.9 million and $2.9 million, respectively, in depreciation expense, which is included in depreciation and amortization expense in the condensed consolidated statements of operations. For the six months ended June 30, 2025 and 2024, the Company recognized $7.7 million and $5.8 million,
9

Table of Contents
respectively, in depreciation expense, which is included in depreciation and amortization expense in the condensed consolidated statements of operations.
Income Taxes
The Company determines the income tax provision for interim periods using an estimate of the Company’s annual effective tax rate, applied to year-to-date results, adjusted for discrete items arising in that quarter. In each quarter, the Company updates its estimated annual effective tax rate, and if the estimated annual effective tax rate changes, a cumulative catch-up adjustment is recorded in that quarter. The Company applied the intra-period tax allocation rules to allocate income taxes between continuing operations and discontinued operations as prescribed in U.S. GAAP, where the tax effect of income (loss) before income taxes from continuing operations is computed without regard to the tax effects of income (loss) before income taxes from the other categories.
On July 4, 2025, the “One Big Beautiful Bill Act” was signed into law in the U.S., which contains a broad range of tax reform provisions. The Company is evaluating the provisions of the legislation and the potential effects on its estimated annual effective tax rate, financial position, results of operations, and cash flows.
Segment Reporting
The Company operates a Medicare-centric, capitated line of business and is organized as a single operating and reportable segment based on the manner in which the Chief Executive Officer, who is the Chief Operating Decision Maker (“CODM”), evaluates performance and makes decisions about how to allocate resources. Segment asset information, which is presented on the consolidated balance sheet, is not used by the CODM to assess performance and make decisions about how to allocate resources. The Company's segment measure of profit or loss is consolidated net income (loss). The CODM uses the segment measure of profit or loss to assess performance and make resource allocation decisions, primarily through periodic budgeting and company performance reviews. Significant expense categories included within the segment measure of profit or loss that are regularly provided to the CODM include medical services expense, other medical expense, and platform support costs. Medical services expense and other medical expense amounts are included in the consolidated statements of operations. Platform support costs were $37.4 million and $41.7 million for the three months ended June 30, 2025 and 2024, respectively. For the three months ended June 30, 2025 and 2024, other segment items, which consists of general and administrative expenses (excluding platform support costs), depreciation and amortization, other income (expense), net, income tax benefit (expense), and results from discontinued operations, were $14.5 million and $21.2 million, respectively. Platform support costs were $81.7 million and $87.4 million for the six months ended June 30, 2025 and 2024, respectively. For the six months ended June 30, 2025 and 2024, other segment items, which consists of general and administrative expenses (excluding platform support costs), depreciation and amortization, other income (expense), net, income tax benefit (expense), and results from discontinued operations, were $8.9 million and $56.6 million, respectively.
Recent Accounting Pronouncements
In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which amends certain disclosure requirements related to income taxes. The amendments in ASU 2023-09 require public business entities on an annual basis to: (i) disclose specific categories in the rate reconciliation and (ii) provide additional information for reconciling items that meet a quantitative threshold. The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. The amendments in ASU 2023-09 can be applied on a prospective basis or retrospective application. Early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASU 2023-09 on its disclosures.
In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”). In January 2025, the FASB issued Accounting Standards Update (“ASU”) 2025-01, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date (“ASU 2025-01”). The amendments in ASU 2024-03 require public business entities to disclose, on an annual and interim basis, disaggregated information about certain income statement expense line items by breaking down certain expense line items into specified natural expense categories, including purchases of inventory, employee compensation, deprecation, intangible asset amortization, and depletion. The amendments in ASU 2024-03 are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The amendments in
10

Table of Contents
ASU 2024-03 can be applied on a prospective basis or retrospective basis and early adoption is permitted. The amendments in ASU 2025-01 clarify the effective date of ASU 2024-03 stating that all public business entities are required to adopt the update in annual reporting periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. ASU 2025-01 does not change the effective date of ASU 2024-03 but was issued to provide clarity on the effective date for public business entities that do not have a calendar year-end. The Company is currently evaluating the potential impact of the adoption of ASU 2024-03 and ASU 2025-01 on its disclosures.

NOTE 3. Revenue, Receivables, and Concentration of Credit Risk

Medical Services Revenue
Medical services revenue consists of capitation fees under contracts with various Medicare Advantage payors (“payors”). Under the typical capitation arrangement, the Company is entitled to monthly per-member, per-month (“PMPM”) fees to provide a defined range of healthcare services for Medicare Advantage health plan members (“members”) attributed to the Company’s contracted primary care physicians. In certain of the Company’s payor arrangements, it is also financially responsible for Medicare Part D pharmaceutical costs for prescriptions rendered to members. PMPM fees are determined as a percent of the premium payors receive from CMS for these members. The Company generally accepts full financial risk for members attributed to its contracted primary care physicians and therefore is responsible for the cost of all healthcare services required by those members. Fees are generally recorded gross in revenue because the Company is acting as a principal in coordinating and controlling the range of services provided (other than clinical decisions) under its capitation contracts with payors. Capitation contracts with payors are generally multi-year arrangements and have a single performance obligation that constitutes a series, as defined by Accounting Standards Codification (“ASC”) 606, Revenue From Contracts With Customers (“ASC 606”), to stand ready on a monthly basis to provide all aspects of necessary medical care to members for the contracted period. The Company recognizes revenue in the month in which eligible members are entitled to receive healthcare benefits during the contract term.
The transaction price for the Company’s capitation contracts is variable, as the PMPM fees to which the Company is entitled are subject to periodic adjustment under CMS’s risk adjustment payment methodology. CMS deploys a risk adjustment model that determines premiums paid to all payors according to each member’s health status and certain demographic factors. Under this risk adjustment methodology, CMS calculates the risk adjusted premium payment using diagnosis data from various settings. The Company and healthcare providers collect and submit the necessary and available diagnosis data to payors and such data is utilized by the Company to estimate risk adjustment payments to be received in subsequent periods. Risk adjustment-related revenues are estimated using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. PMPM fees are also subject to adjustment for incentives or penalties based on the achievement of certain quality metrics defined in the Company’s contracts with payors. The Company recognizes incentive revenue as earned using the most likely amount methodology and only to the extent that it is probable that a significant reversal of incentive revenue will not occur once any uncertainty is resolved.
Neither the Company nor any of its affiliates is a registered insurance company because state law in the states in which it operates does not require such registration for risk-bearing providers.
Receivables
Receivables primarily consist of amounts due under capitation contracts with various payors. Receivables due under capitation contracts are recorded monthly based on reports received from payors and management’s estimate of risk adjustment payments to be received in subsequent periods for open performance years. Receivables are recorded at the amount expected to be realized.
Concentration
The Company contracts with various payors whereby the Company is entitled to monthly PMPM fees to provide a defined range of healthcare services for members attributed to its contracted primary care physicians. The Company generally accepts full financial risk for such members and therefore is responsible for the cost of all healthcare services required by them. Substantially all of the Company’s receivable balances are from a small number of payors. Revenue from Medicare Advantage payors constitutes substantially all of the Company’s total revenue for the three and six months ended June 30, 2025 and 2024.
11

Table of Contents
The following table provides the Company’s revenue concentration with respect to major payors as a percentage of the Company’s total revenues:

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Payor A | 14 | % |  | 22 | % |  | 15 | % |  | 22 | %
Payor B | 14 | % |  | 19 | % |  | 15 | % |  | 17 | %
Payor C | 13 | % |  | * |  | 12 | % |  | *
Payor D | 10 | % |  | * |  | * |  | *
Payor E | 12 | % |  | * |  | 11 | % |  | *

___________________________________________
*Less than 10% of total revenues.
The following table provides the Company’s concentration of credit risk with respect to major payors as a percentage of receivables, net:

| June 30, 2025 |  | December 31, 2024
Payor B | * |  | 11 | %
Payor C | 11 | % |  | 12 | %
Payor D | 13 | % |  | 13 | %
Payor E | 14 | % |  | 15 | %

___________________________________________
*Less than 10% of total receivables.

NOTE 4. Marketable Securities and Fair Value Measurements

Marketable Securities
The following table summarizes the Company’s marketable securities (in thousands):

| June 30, 2025 |  | December 31, 2024
| Amortized Cost |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Fair Value |  | Amortized Cost |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Fair Value
Corporate debt securities | $ | 26,330 |  |  | $ | 29 |  |  | $ | (2) |  |  | $ | 26,357 |  |  | $ | 110,820 |  |  | $ | 91 |  |  | $ | (204) |  |  | $ | 110,707 |
U.S. Treasury notes | 128,575 |  |  | 712 |  |  | (59) |  |  | 129,228 |  |  | 101,059 |  |  | 184 |  |  | (213) |  |  | 101,030 |
| $ | 154,905 |  |  | $ | 741 |  |  | $ | (61) |  |  | $ | 155,585 |  |  | $ | 211,879 |  |  | $ | 275 |  |  | $ | (417) |  |  | $ | 211,737 |

For the three months ended June 30, 2025, the Company recognized total interest income (included in other income (expense), net in the condensed consolidated statements of operations) of $3.6 million, of which $2.6 million was related to its marketable securities investments and $1.0 million was related to interest on cash and cash equivalent balances. For the three months ended June 30, 2024, the Company recognized total interest income (included in other income (expense), net in the condensed consolidated statements of operations) of $4.8 million, of which $3.3 million was related to its marketable securities investments and $1.5 million was related to interest on cash and cash equivalent balances. For the six months ended June 30, 2025, the Company recognized total interest income (included in other income (expense), net in the condensed consolidated statements of operations) of $7.9 million, of which $5.7 million was related to its marketable securities investments and $2.2 million was related to interest on cash and cash equivalent balances. For the six months ended June 30, 2024, the Company recognized total interest income (included in other income (expense), net in the condensed consolidated statements of operations) of $10.2 million, of which $7.2 million was related to its marketable securities investments and $3.0 million was related to interest on cash and cash equivalent balances.
12

Table of Contents
The following table summarizes the Company’s marketable securities maturity as of June 30, 2025 (in thousands):

Year |  | Amortized Cost |  | Fair Value
2025 |  | $ | 40,260 |  |  | $ | 40,248 |
2026 |  | 62,145 |  |  | 62,389 |
2027 |  | 27,966 |  |  | 28,194 |
2028 |  | 24,534 |  |  | 24,754 |
|  | $ | 154,905 |  |  | $ | 155,585 |

The following table summarizes the Company’s marketable securities with gross unrealized losses by security type aggregated by the length of time the investments have been in a continuous unrealized loss position as of June 30, 2025 (in thousands):

| Less Than 12 Months |  | 12 Months or Greater
| Fair Value |  | Gross Unrealized Losses |  | Fair Value |  | Gross Unrealized Losses
Corporate debt securities | $ | 747 |  |  | $ | — |  |  | $ | 3,999 |  |  | $ | 2 |
U.S. Treasury notes | 25,613 |  |  | 55 |  |  | 12,985 |  |  | 4 |
| $ | 26,360 |  |  | $ | 55 |  |  | $ | 16,984 |  |  | $ | 6 |

The following table summarizes the Company’s marketable securities with gross unrealized losses by security type aggregated by the length of time the investments have been in a continuous unrealized loss position as of December 31, 2024 (in thousands):

| Less Than 12 Months |  | 12 Months or Greater
| Fair Value |  | Gross Unrealized Losses |  | Fair Value |  | Gross Unrealized Losses
Corporate debt securities | $ | — |  |  | $ | — |  |  | $ | 73,128 |  |  | $ | 204 |
U.S. Treasury notes | 25,295 |  |  | 104 |  |  | 38,787 |  |  | 109 |
| $ | 25,295 |  |  | $ | 104 |  |  | $ | 111,915 |  |  | $ | 313 |

The Company’s unrealized losses from marketable securities as of June 30, 2025 and December 31, 2024 were caused primarily by interest rate increases. As of June 30, 2025, all of the Company’s marketable securities carry an investment grade rating by nationally recognized statistical rating organizations. The Company does not intend to sell marketable securities that are in an unrealized loss position, and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be maturity. There was no allowance for credit losses on available-for-sale marketable securities at June 30, 2025 or December 31, 2024.
Fair Value Measurements
The Company’s financial instruments consist of cash and cash equivalents, restricted cash and equivalents, marketable securities, receivables, other liabilities, accounts payable, certain accrued expenses, and borrowings which consist of a term loan and a revolving credit facility. The carrying values of the financial instruments classified as current in the consolidated balance sheets approximate their fair values due to their short-term maturities. The Company's cash and cash equivalents are classified within Level 1 of the fair value hierarchy. The carrying values of the term loan and revolving credit facility are a reasonable estimate of fair value because the interest rates on such borrowings approximate market rates as of the reporting date. Such borrowings are classified within Level 2 of the fair value hierarchy. During the three and six months ended June 30, 2025 and 2024, there were no material transfers of financial assets or liabilities within the fair value hierarchy.
The Company measures and discloses the fair value of nonfinancial and financial assets and liabilities utilizing a hierarchy of valuation techniques based on whether the inputs to a fair value measurement are considered to be observable or unobservable in a marketplace. Observable inputs reflect market data obtained from independent sources, while
13

Table of Contents
unobservable inputs reflect the Company’s market assumptions. This hierarchy requires the use of observable market data when available. These inputs have created the following fair value hierarchy:
•Level 1—quoted prices for identical instruments in active markets;
•Level 2—quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which significant inputs and significant value drivers are observable in active markets; and
•Level 3—fair value measurements derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
The table below summarizes the Company’s financial instruments measured at fair value on a recurring basis (in thousands):

| June 30, 2025 |  | December 31, 2024
| Level 1 |  | Level 2 |  | Level 3 |  | Level 1 |  | Level 2 |  | Level 3
Marketable securities: |  |  |  |  |  |  |  |  |  |  |
Corporate debt securities | $ | — |  |  | $ | 26,357 |  |  | $ | — |  |  | $ | — |  |  | $ | 110,707 |  |  | $ | — |
U.S. Treasury notes | 129,228 |  |  | — |  |  | — |  |  | 101,030 |  |  | — |  |  | — |
| $ | 129,228 |  |  | $ | 26,357 |  |  | $ | — |  |  | $ | 101,030 |  |  | $ | 110,707 |  |  | $ | — |

NOTE 5. Other Assets

The following table summarizes the Company’s other assets (in thousands):

| June 30, 2025 |  | December 31, 2024
Loans to physician partners | $ | 39,381 |  |  | $ | 63,155 |
Health plan deposits | 2,051 |  |  | 2,051 |
Equity method investments(1) | 77,906 |  |  | 61,756 |
Right-of-use lease assets | 8,838 |  |  | 8,783 |
Other | 14,921 |  |  | 15,391 |
| $ | 143,097 |  |  | $ | 151,136 |

___________________________________________
(1)See Note 14 for additional discussion related to the Company's equity method investments.
Loans to Physician Partners
Loans to physician partners primarily represent loans in connection with taxes payable on shares distributed to them in connection with the IPO. These loans mature between 2026 and 2031 with nominal interest compounding annually and no prepayment penalties. At June 30, 2025, $21.4 million of these loans were reclassed to Prepaid expenses and other current assets, net on the condensed consolidated balance sheet as the maturities were less than 12 months. Such loans are stated at the amount expected to be collected.

NOTE 6. Medical Claims and Related Payables

Medical services expense represents costs incurred for medical services provided to members by physicians, hospitals and other ancillary providers for which the Company is financially responsible and are paid by payors with whom the Company has contracted. Medical services expenses are recognized in the period in which services are provided and include estimates of claims that have been incurred but have either not yet been received, processed, or paid and as such, not reported.
Such estimates are developed using actuarial methods commonly used by health insurance actuaries that include a number of factors and assumptions including medical service utilization trends, changes in membership, observed medical
14

Table of Contents
cost trends, historical claim payment patterns and other factors. Generally, for the most recent months, the Company estimates claim costs incurred by applying observed medical cost trend factors to the average PMPM medical costs incurred in prior months for which more complete claims data are available.
Each period, the Company re-examines previously established medical claims payable estimates based on actual claim submissions and other changes in facts and circumstances. As more complete claims information becomes available, the Company adjusts its estimates and recognizes those changes in estimates in the period in which the change is identified. The difference between the estimated liability and the actual settlements of claims is recognized in the period the claims are settled. The Company’s medical claims payable balance represents management’s best estimate of its liability for unpaid medical costs as of June 30, 2025 and 2024. The Company uses judgment to determine the appropriate assumptions for developing the required estimates.
The following table presents the components of changes in medical claims and related payables (in thousands):

| June 30,
| 2025 |  | 2024
Medical claims and related payables, beginning of the year | $ | 918,395 |  |  | $ | 723,071 |
Components of incurred costs related to: |  |  |
Current year | 2,810,528 |  |  | 2,802,803 |
Prior years | 36,584 |  |  | 15,099 |
| 2,847,112 |  |  | 2,817,902 |
Claims paid related to: |  |  |
Current year | (1,821,175) |  |  | (1,806,692) |
Prior years | (930,606) |  |  | (650,106) |
| (2,751,781) |  |  | (2,456,798) |
Medical claims and related payables, end of the period | $ | 1,013,726 |  |  | $ | 1,084,175 |

Medical claims and related payables also include $28.5 million and $13.3 million, as of June 30, 2025 and December 31, 2024, respectively, that is recoverable from other parties under risk sharing arrangements and is presented as prepaid expenses and other current assets, net in the condensed consolidated balance sheets.

NOTE 7. Other Liabilities

The following table summarizes the Company’s other liabilities (in thousands):

| June 30, 2025 |  | December 31, 2024
Other long-term contingencies | $ | 35,000 |  |  | $ | 49,000 |
Lease liabilities, long-term | 6,428 |  |  | 6,599 |
Equity method liabilities – CMS ACO Models(1) | 10,355 |  |  | 12,290 |
Other | 3,095 |  |  | 8,232 |
| $ | 54,878 |  |  | $ | 76,121 |

__________________________________________
(1)See Note 14 for additional discussion related to the Company's equity method liabilities related to its CMS ACO Models investments.
As of June 30, 2025 and December 31, 2024, the Company’s accruals for contingent liabilities related to unasserted claims were $35.0 million and $49.0 million, respectively.

NOTE 8. Debt

On February 18, 2021, the Company executed a credit facility agreement (as amended by the First Amendment to Credit Agreement, dated as of March 1, 2021 and the Second Amendment to Credit Agreement, dated as of May 25, 2023, the “Credit Facility”). The Credit Facility includes: (i) a $100.0 million secured term loan facility (the “Secured Term Loan
15

Table of Contents
Facility”) and (ii) a $100.0 million senior secured revolving credit facility (the “Secured Revolving Facility”) with a capacity to issue standby letters of credit in certain circumstances up to a maximum of $100.0 million. Subject to specified conditions and receipt of commitments, the Secured Term Loan Facility may be expanded (or a new term loan facility, revolving credit facility or letter of credit facility added) by up to (i) $50.0 million plus (ii) an additional amount determined in accordance with a formula tied to repayment of certain of the Company’s indebtedness. The maturity date of the Credit Facility is February 18, 2026.
As of June 30, 2025, the Company had $35.0 million outstanding under the Secured Term Loan Facility and availability under the Secured Revolving Facility was $19.4 million, as the Company had outstanding letters of credit totaling $80.6 million. The standby letters of credit are automatically extended without amendment for one-year periods, unless the Company notifies the institution in advance of the expiration date that the letter will be terminated. No amounts have been drawn on the outstanding letters of credit as of June 30, 2025.
Effective with the Second Amendment to Credit Agreement on May 25, 2023, the Company transitioned to the Secured Overnight Financing Rate (“SOFR”) as a benchmark interest rate used in the Credit Agreement. At the Company’s option, borrowings under the Credit Facility can be either: (i) SOFR Rate Loans, (ii) Daily Simple SOFR Rate Loans, or (iii) Base Rate Loans. Daily Simple SOFR Rate Loans and SOFR Rate Loans bear interest at a rate equal to the sum of 3.50% and the higher of (a) SOFR, as defined in the Credit Agreement, and (b) 0%. Base Rate Loans bear interest at a rate equal to the sum of 2.50% and the highest of: (a) 0.50% in excess of the overnight federal funds rate, (b) the prime rate established by the administrative agent from time to time, (c) the one-month SOFR rate (adjusted for maximum reserves) plus 1.00% and (d) 0%. Additionally, the Company pays a commitment fee on the unfunded Secured Revolving Facility amount of 0.375%. The Company must also pay customary letter of credit fees. As of June 30, 2025, the effective interest rate on the Secured Term Loan Facility was 8.279%.
The Credit Facility is guaranteed by certain of the Company’s subsidiaries, including those identified as VIEs, and contain customary covenants including, among other things, limitations on restricted payments including: (i) dividends and distributions from restricted subsidiaries, (ii) requirements of minimum financial ratios, and (iii) limitation on additional borrowings based on certain financial ratios. Failure to meet any of these covenants could result in an event of default under the Credit Agreement. If an event of default occurs, the lenders could elect to declare all amounts outstanding under the Credit Agreement to be immediately due and payable. The Company was in compliance with all covenants under the Credit Facility.

NOTE 9. Commitments and Contingencies

Legal Proceedings
From time to time, the Company is a party to, or has a significant relationship to, legal proceedings, lawsuits, and other claims that arise in the ordinary course of the Company's business. Except as described in this Note 9, the Company is not aware of any other legal proceedings or claims that it believes may have, individually or taken together, a material adverse effect on the Company's business, prospects, financial condition, results of operations or cash flows. The Company’s policy is to expense legal costs as they are incurred.
In February and March 2024, three class action lawsuits were filed and later consolidated as one matter captioned In re agilon health, inc. Securities Litigation, 1:24-cv-00297 (W.D. Tex.) (the “Consolidated Securities Matter”). The Consolidated Securities Matter names the Company and certain current and former members of the Company’s executive team and Board of Directors as defendants, among others. The Consolidated Securities Matter generally asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and under Sections 11, 12(a)(2) and 15 of the Securities Act of 1933, as amended (the “Securities Act”), in connection with statements made between April 2021 and February 2024 in the Company’s annual and quarterly reports, investor presentations, and earnings releases related to, among other things, the Company’s financial guidance, medical margin and Adjusted EBITDA results, growth strategy, and data management. The Consolidated Securities Matter seeks compensatory damages, judgment interest, attorney’s fees and costs, and other unspecified equitable and/or injunctive relief. The Company and other defendants filed motions to dismiss the complaint on November 8, 2024, and the motion is now fully submitted and pending before the Court. The Company intends to vigorously oppose the complaint, but is unable to predict the outcome or estimate any ultimate individual or aggregate amount of monetary liability or financial impact due to the early stages of the litigation.
In May and October 2024, two putative stockholder derivative class action lawsuits were filed: (1) Douglas v. Steven J. Sell et al., 1:24-cv-00531 (W.D. Tex.) and (2) Bingham v. Steven J. Sell et al., 1:24-cv-01181 (W.D. Tex.) (the
16

Table of Contents
“Derivative Matters”). The Derivative Matters name the Company and certain current and former members of the Company’s executive team and Board of Directors as defendants. The Derivative Matters generally assert claims under Sections 14(a) and 10(b) of the Exchange Act, as well as common law claims including breach of fiduciary duty, among others, in connection with statements made between April 2021 and February 2024 in the Company’s annual and quarterly reports, investor presentations, and earnings releases related to, among other things, the Company’s financial guidance, medical margin and Adjusted EBITDA results, growth strategy, and data management. The Douglas lawsuit also asserts claims under Section 20(a) of the Exchange Act in connection with the same allegations and seeks contribution under Section 11(f) of the Securities Act and Section 21D of the Exchange Act. The Derivative Matters seek compensatory damages, restitution, punitive damages, attorney’s fees and costs, and other relief. The plaintiff in the Douglas action also seeks corporate governance reforms. The Derivative Matters were consolidated in November 2024 into In Re agilon health, inc. Shareholder Derivative Litigation, 1:24-cv-00531-DII. The consolidated derivative matter is currently stayed, pending resolution of the motion to dismiss in the Consolidated Securities Matter. The Company intends to vigorously oppose the complaint, but is unable to predict the outcome or estimate any ultimate individual or aggregate amount of monetary liability or financial impact due to the early stage of the litigation.

NOTE 10. Common Stock

Common Stock
2025. During the three months ended June 30, 2025, the Company issued approximately 1.3 million shares of common stock primarily in connection with vesting of stock-based awards. During the six months ended June 30, 2025, the Company issued approximately 2.1 million shares of common stock primarily in connection with vesting of stock-based awards.
2024. During the three months ended June 30, 2024, the Company issued approximately 0.6 million shares of common stock primarily in connection with exercises and vesting of stock-based awards. During the six months ended June 30, 2024, the Company issued approximately 3.1 million shares of common stock primarily in connection with exercises and vesting of stock-based awards. Additionally, during the six months ended June 30, 2024, the Company issued approximately 2.0 million shares of common stock to settle liabilities related to the exchange of common stock for reduced physician partner compensation percentage in certain ACO REACH entities.

NOTE 11. Net Income (Loss) Per Common Share

Basic net income (loss) per common share (“EPS”) is computed based upon the weighted average number of common shares outstanding. Diluted net income (loss) per common share is computed based upon the weighted average number of common shares outstanding plus the impact of common shares issuable from the assumed conversion of stock options, certain performance restricted stock units, and unvested restricted stock units. Only those instruments having a dilutive impact on basic net income (loss) per share are included in diluted net income (loss) per share during the periods presented.
17

Table of Contents
The following table illustrates the computation of basic and diluted EPS (in thousands, except per share amounts):

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Numerator |  |  |  |  |  |  |
Income (loss) from continuing operations | $ | (104,370) |  |  | $ | (30,662) |  |  | $ | (106,258) |  |  | $ | (27,415) |
Noncontrolling interests’ share in (earnings) loss from continuing operations | — |  |  | (20) |  |  | — |  |  | (50) |
Net income (loss) attributable to common stockholders before discontinued operations | (104,370) |  |  | (30,682) |  |  | (106,258) |  |  | (27,465) |
Income (loss) from discontinued operations | — |  |  | — |  |  | 14,000 |  |  | (9,281) |
Net income (loss) attributable to common stockholders | $ | (104,370) |  |  | $ | (30,682) |  |  | $ | (92,258) |  |  | $ | (36,746) |
Denominator |  |  |  |  |  |  |
Weighted average shares outstanding – basic and diluted | 413,836 |  | 411,271 |  | 413,388 |  | 409,152
Net income (loss) per share attributable to common stockholders |  |  |  |  |  |  |
Net income (loss) per common share from continuing operations, basic and diluted | $ | (0.25) |  |  | $ | (0.07) |  |  | $ | (0.25) |  |  | $ | (0.07) |
Net income (loss) per common share from discontinued operations, basic and diluted | $ | — |  |  | $ | — |  |  | $ | 0.03 |  |  | $ | (0.02) |

The following table provides the potential shares of common stock that were excluded from the calculation of diluted net income (loss) per share attributable to common stockholders because their effect would have been anti-dilutive (in thousands):

| June 30,
| 2025 |  | 2024
Stock options | 20,980 |  | 17,421
Restricted stock units | 25,623 |  | 20,177

NOTE 12. Goodwill and Amortizable Intangible Assets

As of both June 30, 2025 and December 31, 2024, the Company’s goodwill balance was $24.1 million. There were no events or circumstances that warranted an interim impairment test for goodwill during the six months ended June 30, 2025.
As of June 30, 2025 and December 31, 2024, the Company’s gross carrying amount of amortizable intangible assets was $122.8 million and $123.8 million, respectively, with accumulated amortization of $57.2 million and $51.0 million, respectively. For the three months ended June 30, 2025 and 2024, the Company recognized $3.4 million and $3.0 million, respectively, in amortization expense, which is included in depreciation and amortization expense in the condensed consolidated statements of operations. For the six months ended June 30, 2025 and 2024, the Company recognized $6.5 million and $6.0 million, respectively, in amortization expense, which is included in depreciation and amortization expense in the condensed consolidated statements of operations.
18

Table of Contents

NOTE 13. Supplemental Cash Flow Information

The following table provides supplemental cash flow information (in thousands):

| Six Months Ended June 30,
| 2025 |  | 2024
Supplemental cash flow information: |  |  |
Interest paid | $ | 2,659 |  |  | $ | 1,981 |
Income taxes paid | 480 |  |  | 355 |
Supplemental disclosure of non-cash investing and financing activities: |  |  |
Right-of-use asset obtained in exchange for new operating lease liability | 1,602 |  |  | 326 |
Settlement of liabilities through issuance of stock | — |  |  | 15,230 |

The following table summarizes cash, cash equivalents and restricted cash equivalents (in thousands):

| June 30, 2025 |  | December 31, 2024
Cash and cash equivalents | $ | 171,416 |  |  | $ | 188,231 |
Restricted cash and equivalents(1) | — |  |  | 5,629 |
Cash, cash equivalents and restricted cash equivalents | $ | 171,416 |  |  | $ | 193,860 |

___________________________________________
(1)Restricted cash and equivalents primarily consist of amounts used as collateral to secure letters of credit that the Company is required to maintain pursuant to contracts with payors.

NOTE 14. Variable Interest Entities

Consolidated Variable Interest Entities
agilon health, inc.’s consolidated assets and liabilities as of June 30, 2025 and December 31, 2024 include certain assets of VIEs that can only be used to settle the liabilities of the related VIE. The VIE creditors do not have recourse to agilon health, inc.
agilon health, inc.’s consolidated assets and liabilities include VIE assets and liabilities as follows (in thousands):

| June 30, 2025 |  | December 31, 2024
Assets |  |  |
Cash and cash equivalents | $ | 57,361 |  |  | $ | 78,650 |
Restricted cash equivalents | — |  |  | 5,627 |
Receivables, net | 1,046,335 |  |  | 1,015,753 |
Prepaid expenses and other current assets, net | 31,599 |  |  | 17,725 |
Property and equipment, net | 1,114 |  |  | 1,255 |
Intangible assets, net | 43,651 |  |  | 49,406 |
Other assets, net | 5,584 |  |  | 4,790 |
Liabilities |  |  |
Medical claims and related payables | 1,042,257 |  |  | 931,664 |
Accounts payable and accrued expenses | 154,932 |  |  | 199,432 |
Other liabilities | 1,381 |  |  | 2,270 |

Risk-bearing Entities. At June 30, 2025, the Company operates 33 wholly-owned risk-bearing entities (“RBEs”) for the purpose of entering into risk-bearing contracts with payors. Each RBE’s equity at risk is considered insufficient to
19

Table of Contents
finance its activities without additional support, and, therefore, each RBE is considered a VIE. The Company consolidates the RBEs as it has determined that it is the primary beneficiary because it has: (i) the ability to control the activities that most significantly impact the RBEs’ economic performance; and (ii) the obligation to absorb losses or right to receive benefits that could potentially be significant to the RBEs. Specifically, the Company has the unilateral ability and authority, through the RBE governance and management agreements, to make significant decisions about strategic and operating activities of the RBEs, including negotiating and entering into risk-bearing contracts with payors, and approving the RBEs’ annual operating budgets. The Company also has the obligation to fund losses of the RBEs and the right to receive a significant percentage of any financial surplus generated by the RBEs. The assets of the RBEs primarily consist of cash and cash equivalents, receivables, net, intangible assets, net, and other assets. Its obligations primarily consist of medical claims and related payables as well as operating expenses of the RBEs (accounts payable and accrued expenses), including incentive compensation obligations to the Company’s physician partners. On February 18, 2021, the Company executed the Credit Facility, which is guaranteed by certain of the Company’s VIEs. Assets generated by the RBEs (primarily from medical services revenues) may be used, in certain limited circumstances, to settle the Company’s contractual debt obligations.
Unconsolidated Variable Interest Entities
As of June 30, 2025, the Company had 12 equity method investments (liabilities), including 10 wholly-owned CMS ACO Models entities discussed below, that were deemed to be VIEs. The Company has determined that the activities that most significantly impact the performance of these VIEs consist of the allocation of resources to and other decisions related to clinical activities and provider contracting decisions. Because the Company does not have the ability to control these activities due to another party’s control of the VIEs’ board of directors, the Company has determined that it is not the primary beneficiary of and therefore does not consolidate these VIEs. The Company provided support to assist its CMS ACO Models investments in obtaining surety bonds related to risk-bearing capital contributions to CMS. As of June 30, 2025 and December 31, 2024, the CMS ACO Models investments had $131.6 million and $65.2 million, respectively, of outstanding surety bonds. The Company's maximum loss exposure as a result of the Company’s involvement with the unconsolidated VIEs cannot be quantified as the Company has the obligation to provide ongoing operational support to the unconsolidated VIEs, as needed.
Equity Method Investments
The following table summarizes the Company’s equity method investees (in thousands):

| June 30, 2025 |  | December 31, 2024
Equity method investments - Other(1) | $ | 9,378 |  |  | $ | 9,365 |
Equity method investments - CMS ACO Models(1) | 68,528 |  |  | 52,391 |
Equity method liabilities - CMS ACO Models(2) | (10,355) |  |  | (12,290) |

___________________________________________
(1)Included in Other assets, net in the condensed consolidated balance sheets.
(2)Included in Other liabilities in the condensed consolidated balance sheets.
The Company is a partner in 10 wholly-owned CMS ACO Models investments in collaboration with 13 of its physician group partners operating in 12 geographies. The combined summarized operating results of the Company’s CMS ACO Models investments are as follows (in thousands):

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Medical services revenue | $ | 434,806 |  |  | $ | 446,914 |  |  | $ | 848,271 |  |  | $ | 887,074 |
Medical services expense | (401,902) |  |  | (406,921) |  |  | (753,755) |  |  | (805,713) |
Other medical expenses(1) | (17,848) |  |  | (22,268) |  |  | (54,090) |  |  | (47,673) |
Income (loss) from operations(2) | 6,396 |  |  | 11,325 |  |  | 22,609 |  |  | 20,857 |
Net income (loss)(3) | 5,395 |  |  | 9,921 |  |  | 18,072 |  |  | 15,552 |

___________________________________________
20

Table of Contents
(1)The three months ended June 30, 2025 and 2024, includes physician incentive expenses of $8.8 million and $13.7 million, respectively. The six months ended June 30, 2025 and 2024, includes physician incentive expenses of $36.6 million and $30.4 million, respectively.
(2)The three months ended June 30, 2025 and 2024, includes operating expenses for services provided by the Company of $4.3 million and $1.3 million, respectively. The six months ended June 30, 2025 and 2024, includes operating expenses for services provided by the Company of $8.5 million and $2.6 million, respectively.
(3)Included in Income (loss) from equity method investments in the condensed consolidated statements of operations.
The combined summarized balance sheet of the Company’s CMS ACO Models investments are as follows (in thousands):

| June 30, 2025 |  | December 31, 2024
Current assets | $ | 524,238 |  |  | $ | 444,963 |
Noncurrent assets | 1,894 |  |  | 1,894 |
Total assets | 526,132 |  |  | 446,857 |
Current and total liabilities | 467,959 |  |  | 406,756 |

NOTE 15. Discontinued Operations

Discontinued operations is a component of an entity that has either been disposed of or is deemed held-for-sale and, (i) the operations and cash flows of the component have been or will be eliminated from ongoing operations as a result of the disposal transaction, and (ii) the entity will not have any significant continuing involvement in the operations of the component after the disposal transaction. On October 31, 2023, the Company completed the disposition of MDX Hawaii, Inc. and its related operations. The Company’s decision to exit Hawaii and the Independent Practice Association line of business represents a strategic shift that will have a major effect on its operations and financial results. As such, the Company’s Hawaii operations are reflected in the condensed consolidated financial statements as discontinued operations for all periods presented.
The results of discontinued operations are as follows (in thousands):

|  |  | Six Months Ended June 30,
|  |  |  |  | 2025 |  | 2024
Expenses: |  |  |  |  |  |  |
General and administrative |  |  |  |  | $ | — |  |  | $ | 518 |
Income (loss) from operations |  |  |  |  | — |  |  | (518) |
Adjustments on sale of assets, net |  |  |  |  | 14,000 |  |  | (8,763) |
Net income (loss) from discontinued operations attributable to common shares |  |  |  |  | $ | 14,000 |  |  | $ | (9,281) |

21

Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
All references in this report to “agilon,” “the Company”, “we,” “us” or “our” mean agilon health, inc., together with its consolidated subsidiaries. Unless the context suggests otherwise, references to “agilon health, inc.” mean the parent company without its subsidiaries.
Cautionary Language Regarding Forward-Looking Statements
Statements in this Quarterly Report on Form 10-Q (the “Report”) that are not historical factual statements are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Some of the forward-looking statements can be identified by the use of forward-looking terms such as “believes,” “expects,” “may,” “will,” “shall,” “should,” “would,” “could,” “seeks,” “aims,” “projects,” “is optimistic,” “intends,” “plans,” “estimates,” “anticipates” or the negative versions of these words or other comparable terms. Forward-looking statements include, without limitation, all matters that are not historical facts. They appear in several places throughout this Report and include, without limitation, statements regarding our intentions, beliefs, assumptions or current expectations concerning, among other things, our financial position, results of operations, cash flows, prospects, and growth strategies.
Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be outside our control. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Report, we caution you that forward-looking statements are not guarantees of future performance or outcomes and that actual performance and outcomes, including, without limitation, our actual results of operations, financial condition and liquidity, and the development of the market in which we operate, may differ materially from those made in or suggested by the forward-looking statements contained in this Report. In addition, even if our results of operations, financial condition, and cash flows, and the development of the market in which we operate, are consistent with the forward-looking statements contained in this Report, those results or developments may not be indicative of results or developments in subsequent periods. You are therefore cautioned not to place undue reliance on the forward-looking statements included in this report. A number of important factors, including, without limitation, the risks and uncertainties discussed under Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, could cause actual results and outcomes to differ materially from those reflected in the forward-looking statements. Furthermore, new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Report. Factors that could cause actual results and outcomes to differ from those reflected in forward-looking statements include, without limitation:
•our history of net losses and the expectation that our expenses will increase in the future;
•failure to identify and develop successful new geographies, physician partners and payors, or execute upon our growth initiatives;
•success in executing our operating strategies or achieving results consistent with our historical performance;
•medical expenses incurred on behalf of our members may exceed revenues we receive;
•our ability to maintain and secure additional contracts with Medicare Advantage (“MA”) payors on favorable terms, if at all;
•our ability to grow new physician partner relationships sufficient to recover startup costs;
•availability of additional capital, on acceptable terms or at all, to support our business in the future;
•significant reduction in our membership;
•transition to a Total Care Model may be challenging for physician partners;
•public health crises, such as COVID-19, could adversely affect us;
•inaccuracy in estimates of our members’ risk adjustment factors, medical services expense, incurred but not reported claims, and earnings pursuant to payor contracts;
•the impact of restrictive clauses or exclusivity provisions in some of our contracts with physician partners;
•our ability to hire and retain qualified personnel;
•our ability to realize the full value of our intangible assets;
22

Table of Contents
•security breaches, cybersecurity attacks, loss of data and other disruptions to our information systems;
•our ability to protect the confidentiality of our know-how and other proprietary and internally developed information;
•our reliance on our subsidiaries to perform and fund their operations;
•our use of artificial intelligence and machine learning in our business and challenges with properly managing the development and use of these technologies;
•our reliance on a limited number of key payors;
•the limited terms of contracts with our payors and our ability to renew them upon expiration;
•our ability to navigate the changing healthcare payor market;
•our reliance on our payors, physician partners and other providers to operate our business;
•our ability to obtain accurate and complete diagnosis data;
•our reliance on third-party software, data, infrastructure and bandwidth;
•consolidation and competition in the healthcare industry;
•the impact of changes to, and dependence on, federal government healthcare programs;
•uncertain or adverse economic and macroeconomic conditions, including a downturn or decrease in government expenditures;
•regulation of the healthcare industry and our physician partners’ ability to comply with such laws and regulations;
•federal and state investigations, audits and enforcement actions;
•repayment obligations arising out of payor audits;
•negative publicity regarding the managed healthcare industry generally;
•our use, disclosure and processing of personally identifiable information, protected health information, and de-identified data;
•failure to obtain or maintain an insurance license, a certificate of authority or an equivalent authorization;
•changes in tax laws and regulations, or changes in related judgments or assumptions;
•our indebtedness and our potential to incur more debt;
•our dependence on our subsidiaries for cash to fund all of our operations and expenses;
•provisions in our governing documents;
•our ability to achieve a return on investment depends on appreciation in the price of our common stock;
•lawsuits not covered by insurance and securities class action litigation;
•sustainability issues;
•our stock price may be volatile;
•risks related to management transitions, including the search for a permanent CEO, and our ability to effectively manage leadership changes; and
•risks related to other factors discussed under Part I, Item 1A “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
Except as required by law, we do not undertake, and hereby disclaim, any obligation to update any forward-looking statements, which speak only as of the date on which they are made.
23

Table of Contents
The information set forth in this Item 2 is intended to provide readers with an understanding of our financial condition, changes in financial condition, and results of operations and should be read in connection with the accompanying Condensed Consolidated Financial Statements and notes to Condensed Consolidated Financial Statements in Part I, Item 1 of this Report. We will discuss and provide our analysis in the following order:
•Overview and Recent Developments
•Key Financial and Operating Metrics
•Key Components of Our Results of Operations
•Results of Operations
•Non-GAAP Financial Measures
•Liquidity and Capital Resources
•Critical Accounting Estimates
•Recent Accounting Pronouncements
Overview and Recent Developments
Our business is transforming healthcare by empowering the primary care physicians (“PCPs”) to be the agent for change in the communities they serve. We believe that PCPs, with their intimate patient-physician relationships, are best positioned to drive meaningful change in quality, cost, and patient experience when provided with the right infrastructure and payment model. Through our combination of the agilon platform, a long-term partnership model with existing physician groups and a growing network of like-minded physicians, we believe we are poised to revolutionize healthcare for seniors across communities throughout the United States. We believe our purpose-built model provides the necessary capabilities, capital, and business model for existing physician groups to create a Medicare-centric, globally capitated line of business. Our model operates by forming risk-bearing entities (“RBEs”) within local geographies, that enter into arrangements with payors providing for monthly payments to manage the total healthcare needs of our physician partners’ attributed patients (or, global capitation arrangements). The RBEs also contract with agilon to perform certain functions and enter into long-term professional service agreements with one or more anchor physician groups pursuant to which the anchor physician groups receive a base compensation rate and share in the savings from successfully improving quality of care and reducing costs.
Our business model is differentiated by its focus on existing community-based physician groups and is built around three key elements: (1) agilon’s platform; (2) agilon’s long-term physician partnership model; and (3) agilon’s network. With our model, our goal is to remove the barriers that prevent community-based physicians from evolving to a Total Care Model, where the physician is empowered to manage health outcomes and the total healthcare needs of their attributed Medicare patients.
Second Quarter 2025 Results:
•Medicare Advantage members of approximately 497,500 as of June 30, 2025 decreased 3% from June 30, 2024.
•CMS ACO Models (defined below) attributed beneficiaries of approximately 116,000 as of June 30, 2025 decreased 12% from June 30, 2024.
•Total revenue of $1.4 billion decreased 6% from the second quarter of 2024.
•Gross profit of negative $52 million, compared to positive $32 million in the second quarter of 2024.
•Medical margin of negative $53 million, compared to positive of $106 million in the second quarter of 2024.
•Net loss of $104 million, compared to $31 million in the second quarter of 2024.
•Adjusted EBITDA loss of $83 million, compared to $3 million in the second quarter of 2024.
Year to Date 2025 Results as of June 30, 2025:
•Total revenue of $2.9 billion decreased 5% from the first half of 2024.
24

Table of Contents
•Gross profit of negative $2 million, compared to positive $107 million in the first half of 2024.
•Medical margin of $75 million, compared to $263 million in the first half of 2024.
•Net loss of $92 million, compared to $37 million in the first half of 2024.
•Adjusted EBITDA loss of $63 million, compared to earnings of $26 million in the first half of 2024.
Platform Membership Details
Medicare Advantage members decreased 3% from June 30, 2024, which includes market exits during 2024, partially offset by contributions from new geographies and growth within geographies existing prior to 2024. Total members live on the agilon platform at June 30, 2025 include 497,500 Medicare Advantage members and 116,000 attributed CMS ACO Models beneficiaries.
Average Medicare Advantage membership was 497,700 during the second quarter of 2025.
Payor Data Pipeline
In the first quarter of 2025, we implemented a payor data pipeline (the “Model”) and began onboarding certain payors onto the Mode. The Model provides enhanced visibility into member risk profiles and risk adjustment factors by integrating and interpreting the data received from our payor partners. We are continuing the process of onboarding our payors onto the Model.
Key Financial and Operating Metrics
All of our key metrics exclude historical results from our Hawaii operations (which are included as discontinued operations in our condensed consolidated financial statements).
We monitor the following key financial and operating metrics to help us evaluate our business, identify trends affecting our business, formulate business plans and make strategic decisions. We believe the following key metrics are useful in evaluating our business (dollars in thousands):

| As of and For the |  | As of and For the
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2025 |  | 2024 |  | % Change |  | 2025 |  | 2024 |  | % Change
MA members | 497,500 |  | 512,800 |  | (3) |  |  | 497,500 |  | 512,800 |  | (3) |
Medical services revenue | $ | 1,392,039 |  |  | $ | 1,479,579 |  |  | (6) |  |  | $ | 2,921,918 |  |  | $ | 3,080,774 |  |  | (5) |
Gross profit (loss) | $ | (52,427) |  |  | $ | 32,175 |  |  | (263) |  |  | $ | (1,705) |  |  | $ | 107,263 |  |  | (102) |
Medical margin(1) | $ | (53,206) |  |  | $ | 105,519 |  |  | (150) |  |  | $ | 74,806 |  |  | $ | 262,872 |  |  | (72) |
Platform support costs | $ | 37,423 |  |  | $ | 41,687 |  |  | (10) |  |  | $ | 81,661 |  |  | $ | 87,399 |  |  | (7) |
Net income (loss) | $ | (104,370) |  |  | $ | (30,662) |  |  | (240) |  |  | $ | (92,258) |  |  | $ | (36,696) |  |  | (151) |
Adjusted EBITDA(1) | $ | (83,333) |  |  | $ | (2,830) |  |  | (2,845) |  |  | $ | (62,766) |  |  | $ | 26,224 |  |  | (339) |

___________________________________________
(1)Medical margin and Adjusted EBITDA are non-GAAP financial measures. Gross profit (loss) is the most directly comparable financial measure calculated in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) to medical margin. Net income (loss) is the most directly comparable financial measure calculated in accordance with U.S. GAAP to Adjusted EBITDA. See “—Non-GAAP Financial Measures" below for additional information.
Medicare Advantage Members
Our MA members include all individuals enrolled in an MA plan that are attributed to the PCPs on our platform at the end of a given period.
Medical Services Revenue
Our medical services revenue consists of capitation revenue under contracts with various payors. Under the typical capitation arrangement, we are entitled to per member per month (“PMPM”) fees to provide a defined range of healthcare
25

Table of Contents
services for MA health plan members through our contracted physician partners and affiliated PCPs. Such fees are typically based on a defined percentage of corresponding premium that payors receive from the Centers for Medicare & Medicaid Services' (“CMS”). We recognize capitation revenue over the period eligible members are entitled to receive healthcare services.
Gross Profit (Loss)
Gross profit (loss) represents the amount earned from total revenues less medical services expense and other medical expenses. Total revenues include medical services revenue and other operating revenue. The Company’s costs of revenues consist of medical services expense and other medical expenses, which represents the costs that are directly related to providing the services that generate revenue.
The following table presents our gross profit (loss) (dollars in thousands):

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Total revenues | $ | 1,394,982 |  |  | $ | 1,482,758 |  |  | $ | 2,927,764 |  |  | $ | 3,087,112 |
Medical services expense | (1,445,245) |  |  | (1,374,060) |  |  | (2,847,112) |  |  | (2,817,902) |
Other medical expenses(1) | (2,164) |  |  | (76,523) |  |  | (82,357) |  |  | (161,947) |
Gross profit (loss) | $ | (52,427) |  |  | $ | 32,175 |  |  | $ | (1,705) |  |  | $ | 107,263 |

___________________________________________
(1)Represents physician compensation expense related to surplus sharing and other care management expenses that help to create medical cost efficiency. Includes costs in geographies that are in implementation and are not yet generating revenue and investments to grow existing markets. For the three months ended June 30, 2025 and 2024, costs incurred in implementing geographies were $0.2 million and $0, respectively. For the six months ended June 30, 2025 and 2024, costs incurred in implementing geographies were $(1.0) million and $0.6 million, respectively.
Medical Margin
We define medical margin as medical services revenue after medical services expense is deducted. Medical services expense represents costs incurred for medical services provided to our members. As our platform matures over time, we expect medical margin to increase in absolute dollars. However, medical margin PMPM may vary as the percentage of new members brought onto our platform fluctuates. New membership added to the platform is typically dilutive to medical margin PMPM.
See “—Non-GAAP Financial Measures” below for additional information regarding our use of medical margin and a reconciliation of gross profit (loss) to medical margin.
Platform Support Costs
Our platform support costs, which include regionally-based support personnel and other operating costs to support our geographies, are expected to decrease over time as a percentage of revenue as our physician partners add members and our revenue grows. Our operating expenses at the enterprise level include resources and technology to support payor contracting, clinical program development, quality, data management, finance, and legal and compliance functions.
The table below presents costs to support our live geographies and enterprise functions, which are included in general and administrative expenses (dollars in thousands):

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Platform support costs | $ | 37,423 |  |  | $ | 41,687 |  |  | $ | 81,661 |  |  | $ | 87,399 |
% of Revenue | 3 | % |  | 3 | % |  | 3 | % |  | 3 | %

26

Table of Contents
Net Income (Loss) and Adjusted EBITDA
Net income (loss) is the most directly comparable U.S. GAAP measure to Adjusted EBITDA. We define Adjusted EBITDA as net income (loss) adjusted to exclude: (i) income (loss) from discontinued operations, net of income taxes, (ii) interest expense, (iii) income tax expense (benefit), (iv) depreciation and amortization, (v) stock-based compensation expense, (vi) severance and related costs, and (vii) certain other items that are not considered by us in the evaluation of ongoing operating performance. We reflect our share of Adjusted EBITDA for equity method investments by applying our actual ownership percentage for the period to the applicable reconciling items on an entity-by-entity basis.
See “—Non-GAAP Financial Measures” below for additional information regarding our use of Adjusted EBITDA and a reconciliation of net income (loss) to Adjusted EBITDA.
Key Components of Our Results of Operations
Revenues
Medical Services Revenue
Our medical services revenue consists of capitation revenue under contracts with various payors. Under the typical capitation arrangement, we are entitled to PMPM fees to provide a defined range of healthcare services for MA health plan members through our contracted physician partners and affiliated PCPs. Such fees are typically based on a defined percentage of corresponding premium that payors receive from CMS. We recognize capitation revenue over the period eligible members are entitled to receive healthcare services. In certain of our payor arrangements, we are also financially responsible for Medicare Part D pharmaceutical costs for prescriptions rendered to members.
Medical services revenue constitutes substantially all of our total revenue for the three and six months ended June 30, 2025 and 2024.
Operating Expenses
Medical Services Expense
In each of our geographies, a network of physicians, hospitals, and other healthcare providers provide care to our members. Medical services expense represents costs incurred for medical services provided to our members. Our medical services expense trends primarily relate to changes in per visit costs incurred by our members, along with changes in health system and provider utilization of services. Medical services expenses are recognized in the period in which services are provided and include estimates of our obligations for medical services that have been rendered by third parties but for which claims have either not yet been received, processed, or paid.
Other Medical Expenses
Other medical expenses include: (i) partner physician compensation expense and (ii) other provider costs. Partner physician compensation expense represents obligations to our physician partners corresponding to a portion of the surplus generated in our geographies, which is a function of medical services revenues less the sum of medical services expenses, other provider costs and market operating costs, for the respective geography. Physician payment obligations are reconciled quarterly, and settlement payments are typically issued to providers on an annual basis in arrears, with interim payments issued periodically. Other provider costs include payments to support physician-patient engagement, certain other medical costs, and other care management expenses that help to create medical cost efficiency. Other provider costs include costs incurred for geographies that are in implementation and are not yet generating revenue.
General and Administrative
General and administrative expenses consist of market-based support personnel and other operating costs to support our geographies, personnel and other operating costs to support our enterprise functions, and investments to support development and expansion of our physician partners. Our enterprise functions include salaries and related expenses, stock-based compensation (including shares issued under partner physician group equity agreements), operational support expenses, technology infrastructure, finance, and legal, as well as other costs associated with the continued growth of our platform. For the purposes of calculating physician partner incentive expense, we allocate a portion of our enterprise general and administrative expenses to our geographies. General and administrative expenses also include severance and accruals for unasserted claims.
27

Table of Contents
Depreciation and Amortization
Depreciation and amortization expenses are associated with our property and equipment and acquired intangible assets. Depreciation includes expenses associated with computer equipment and software, furniture and fixtures, and leasehold improvements. Amortization primarily includes expenses associated with acquired intangible assets.
Other Income (Expense)
Income (loss) from equity method investments
Income (loss) from equity method investments consists primarily of income associated with our participation in the CMS the Accountable Care Organization Realizing Equity, Access, and Community Health (“ACO REACH”) Model and Shared Savings Program (“MSSP”), (collectively, “CMS ACO Models”).
Other Income (Expense), Net
Other income (expense), net includes interest income, which consists primarily of interest earned on our cash and cash equivalents, restricted cash and equivalents, and marketable securities, including amortization/accretion of discount/premium.
Interest Expense
Interest expense consists primarily of interest expense associated with our outstanding debt, including amortization of debt discounts and issuance costs.
Income Tax Benefit (Expense)
We are subject to corporate U.S. federal, state, foreign, and local income taxation. Deferred tax assets are reduced by a valuation allowance to the extent management believes it is not more likely than not to be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income. Management makes estimates and judgments about future taxable income based on assumptions that are consistent with our plans and estimates.
On July 4, 2025, the “One Big Beautiful Bill Act” was signed into law in the U.S., which contains a broad range of tax reform provisions. We are evaluating the provisions of the legislation and the potential effects on our estimated annual effective tax rate, financial position, results of operations, and cash flows.
Total Discontinued Operations
Total discontinued operations primarily consist of the results of our former Hawaii operations. For certain of our divestiture transactions, we continue to be responsible for any liabilities arising from the business that were incurred prior to the closing date of such transaction, including any fines, penalties, and other sanctions, the payment of claims for medical services incurred prior to the effective date of each transaction, and other contingent liabilities that we currently believe are remote. For additional discussion, see Note 15 to the Condensed Consolidated Financial Statements.
28

Table of Contents
Results of Operations
The following table summarizes key components of our results of operations (dollars in thousands):

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Revenues: |  |  |  |  |  |  |
Medical services revenue | $ | 1,392,039 |  |  | $ | 1,479,579 |  |  | $ | 2,921,918 |  |  | $ | 3,080,774 |
Other operating revenue | 2,943 |  |  | 3,179 |  |  | 5,846 |  |  | 6,338 |
Total revenues | 1,394,982 |  |  | 1,482,758 |  |  | 2,927,764 |  |  | 3,087,112 |
Expenses: |  |  |  |  |  |  |
Medical services expense | 1,445,245 |  |  | 1,374,060 |  |  | 2,847,112 |  |  | 2,817,902 |
Other medical expenses | 2,164 |  |  | 76,523 |  |  | 82,357 |  |  | 161,947 |
General and administrative | 56,281 |  |  | 69,612 |  |  | 122,237 |  |  | 146,034 |
Depreciation and amortization | 7,319 |  |  | 5,907 |  |  | 14,195 |  |  | 11,751 |
Total expenses | 1,511,009 |  |  | 1,526,102 |  |  | 3,065,901 |  |  | 3,137,634 |
Income (loss) from operations | (116,027) |  |  | (43,344) |  |  | (138,137) |  |  | (50,522) |
Other income (expense): |  |  |  |  |  |  |
Income (loss) from equity method investments | 5,412 |  |  | 9,955 |  |  | 18,084 |  |  | 15,639 |
Other income (expense), net | 7,879 |  |  | 4,841 |  |  | 17,140 |  |  | 10,733 |
Interest expense | (1,572) |  |  | (1,697) |  |  | (3,087) |  |  | (2,981) |
Income (loss) before income taxes | (104,308) |  |  | (30,245) |  |  | (106,000) |  |  | (27,131) |
Income tax benefit (expense) | (62) |  |  | (417) |  |  | (258) |  |  | (284) |
Income (loss) from continuing operations | (104,370) |  |  | (30,662) |  |  | (106,258) |  |  | (27,415) |
Discontinued operations: |  |  |  |  |  |  |
Income (loss) before gain (loss) on sales | — |  |  | — |  |  | — |  |  | (518) |
Adjustments on sale of assets, net | — |  |  | — |  |  | 14,000 |  |  | (8,763) |
Total discontinued operations | — |  |  | — |  |  | 14,000 |  |  | (9,281) |
Net income (loss) | (104,370) |  |  | (30,662) |  |  | (92,258) |  |  | (36,696) |
Noncontrolling interests’ share in (earnings) loss | — |  |  | (20) |  |  | — |  |  | (50) |
Net income (loss) attributable to common shares | $ | (104,370) |  |  | $ | (30,682) |  |  | $ | (92,258) |  |  | $ | (36,746) |

29

Table of Contents
The following table summarizes our results of operations as a percentage of total revenues:

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Revenues: |  |  |  |  |  |  |
Medical services revenue | 100 | % |  | 100 | % |  | 100 | % |  | 100 | %
Other operating revenue | — |  |  | — |  |  | — |  |  | — |
Total revenues | 100 |  |  | 100 |  |  | 100 |  |  | 100 |
Expenses: |  |  |  |  |  |  |
Medical services expense | 104 |  |  | 93 |  |  | 97 |  |  | 91 |
Other medical expenses | — |  |  | 5 |  |  | 3 |  |  | 5 |
General and administrative | 4 |  |  | 5 |  |  | 4 |  |  | 5 |
Depreciation and amortization | 1 |  |  | — |  |  | — |  |  | — |
Total expenses | 108 |  |  | 103 |  |  | 105 |  |  | 102 |
Income (loss) from operations | (8) |  |  | (3) |  |  | (5) |  |  | (2) |
Other income (expense): |  |  |  |  |  |  |
Income (loss) from equity method investments | — |  |  | 1 |  |  | 1 |  |  | 1 |
Other income (expense), net | 1 |  |  | — |  |  | 1 |  |  | — |
Interest expense | — |  |  | — |  |  | — |  |  | — |
Income (loss) before income taxes | (7) |  |  | (2) |  |  | (4) |  |  | (1) |
Income tax benefit (expense) | — |  |  | — |  |  | — |  |  | — |
Income (loss) from continuing operations | (7) |  |  | (2) |  |  | (4) |  |  | (1) |
Discontinued operations: |  |  |  |  |  |  |
Income (loss) before gain (loss) on sales | — |  |  | — |  |  | — |  |  | — |
Gain (loss) on sales of assets, net | — |  |  | — |  |  | — |  |  | — |
Total discontinued operations | — |  |  | — |  |  | — |  |  | — |
Net income (loss) | (7) |  |  | (2) |  |  | (3) |  |  | (1) |
Noncontrolling interests’ share in (earnings) loss | — |  |  | — |  |  | — |  |  | — |
Net income (loss) attributable to common shares | (7) | % |  | (2) | % |  | (3) | % |  | (1) | %

Comparison of the Three and Six Months Ended June 30, 2025 to the Three and Six Months Ended June 30, 2024
Medical Services Revenue

| Three Months Ended June 30, |  | Change
(dollars in thousands) | 2025 |  | 2024 |  | $ |  | %
Medical services revenue | $ | 1,392,039 |  |  | $ | 1,479,579 |  |  | $ | (87,540) |  |  | (6) | %
% of total revenues | 100 | % |  | 100 | % |  |  |  |

Medical services revenue decreased for the three months ended June 30, 2025 primarily due to: (i) declines in average membership, which was attributable to the partnership exits during 2024, (ii) lower risk adjustment revenue, including unfavorable prior period development, as a result of additional risk adjustment data received from the payors and
30

Table of Contents
(iii) higher costs associated with prescription drug benefits provided under the Medicare Part D program, which is a reduction to medical services revenue, related to unfavorable prior period development.

| Six Months Ended June 30, |  | Change
(dollars in thousands) | 2025 |  | 2024 |  | $ |  | %
Medical services revenue | $ | 2,921,918 |  |  | $ | 3,080,774 |  |  | $ | (158,856) |  |  | (5) | %
% of total revenues | 100 | % |  | 100 | % |  |  |  |

Medical services revenue decreased for the six months ended June 30, 2025 primarily due to: (i) declines in average membership, which was attributable to the partnership exits during 2024, (ii) lower risk adjustment revenue, including unfavorable prior period development, as a result of additional risk adjustment data received from the payors and (iii) higher costs associated with prescription drug benefits provided under the Medicare Part D program, which is a reduction to medical services revenue, related to unfavorable prior period development.
Medical Services Expense

| Three Months Ended June 30, |  | Change
(dollars in thousands) | 2025 |  | 2024 |  | $ |  | %
Medical services expense | $ | 1,445,245 |  |  | $ | 1,374,060 |  |  | $ | 71,185 |  |  | 5 | %
% of total revenues | 104 | % |  | 93 | % |  |  |  |

Medical services expense increased for the three months ended June 30, 2025 due primarily to an increase in average medical services expense per member of 7%, partially offset by a decline in average membership of 2%, which was attributable to the partnership exits during 2024.

| Six Months Ended June 30, |  | Change
(dollars in thousands) | 2025 |  | 2024 |  | $ |  | %
Medical services expense | $ | 2,847,112 |  |  | $ | 2,817,902 |  |  | $ | 29,210 |  |  | 1 | %
% of total revenues | 97 | % |  | 91 | % |  |  |  |

Medical services expense increased for the six months ended June 30, 2025 due primarily to an increase in average medical services expense per member of 5%, partially offset by a decline in average membership of 4%, which was attributable to the partnership exits during 2024.
Other Medical Expenses

| Three Months Ended June 30, |  | Change
(dollars in thousands) | 2025 |  | 2024 |  | $ |  | %
Other medical expenses | $ | 2,164 |  |  | $ | 76,523 |  |  | $ | (74,359) |  |  | (97) | %
% of total revenues | — | % |  | 5 | % |  |  |  |

Other medical expenses decreased by $74.4 million, or 97%, for the three months ended June 30, 2025 compared to the same period in 2024. Partner physician incentive expense decreased by $65.2 million to $(34.9) million in 2025 compared to $30.3 million in the same period in 2024 as a result of the partnership exits during 2024 and recent losses generated in certain of our geographies, which is a function of medical services revenues less the sum of medical services expenses, other provider costs and market operating costs, for the respective geography. Other provider costs decreased by $9.3 million to $36.9 million in 2025 compared to $46.2 million in the same period in 2024, resulting from the partnership exits during 2024.
31

Table of Contents

| Six Months Ended June 30, |  | Change
(dollars in thousands) | 2025 |  | 2024 |  | $ |  | %
Other medical expenses | $ | 82,357 |  |  | $ | 161,947 |  |  | $ | (79,590) |  |  | (49) | %
% of total revenues | 3 | % |  | 5 | % |  |  |  |

Other medical expenses decreased by $79.6 million, or 49%, for the six months ended June 30, 2025 compared to the same period in 2024. Partner physician incentive expense decreased by $71.0 million to $9.1 million in 2025 compared to $80.1 million in the same period in 2024 as a result of the partnership exits during 2024 and recent losses generated in certain of our geographies, which is a function of medical services revenues less the sum of medical services expenses, other provider costs and market operating costs, for the respective geography. Other provider costs decreased by $6.9 million to $74.3 million in 2025 compared to $81.2 million in the same period in 2024, resulting from the partnership exits during 2024.
General and Administrative

| Three Months Ended June 30, |  | Change
(dollars in thousands) | 2025 |  | 2024 |  | $ |  | %
General and administrative | $ | 56,281 |  |  | $ | 69,612 |  |  | $ | (13,331) |  |  | (19) | %
% of total revenues | 4 | % |  | 5 | % |  |  |  |

General and administrative expenses decreased $13.3 million, or 19%, for the three months ended June 30, 2025 compared to the same period in 2024. Operating costs to support our live geographies and enterprise functions (platform support costs) decreased to $37.4 million in 2025, compared to $41.7 million in the same period in 2024. Investments to support geography entry decreased to $4.2 million in 2025, compared to $4.8 million in the same period in 2024 due to decreased costs associated with our geographies that are expected to become operational in subsequent calendar years and the expansion into existing geographies. In aggregate, costs incurred for severance, transaction related costs, and stock-based compensation expense decreased $8.4 million in 2025 primarily due to a reduction in severance and the cancellation of certain stock-based instruments during the second half of 2024.

| Six Months Ended June 30, |  | Change
(dollars in thousands) | 2025 |  | 2024 |  | $ |  | %
General and administrative | $ | 122,237 |  |  | $ | 146,034 |  |  | $ | (23,797) |  |  | (16) | %
% of total revenues | 4 | % |  | 5 | % |  |  |  |

General and administrative expenses decreased $23.8 million, or 16%, for the six months ended June 30, 2025 compared to the same period in 2024. Operating costs to support our live geographies and enterprise functions (platform support costs) decreased to $81.7 million in 2025, compared to $87.4 million in the same period in 2024. Investments to support geography entry decreased to $10.8 million in 2025, compared to $15.3 million in the same period in 2024 due to decreased costs associated with our geographies that are expected to become operational in subsequent calendar years and the expansion into existing geographies. In aggregate, costs incurred for severance, transaction related costs, and stock-based compensation expense decreased $13.5 million in 2025 primarily due to a reduction in severance and the cancellation of certain stock-based instruments during the second half of 2024.
Income (loss) from equity method investments

| Three Months Ended June 30, |  | Change
(dollars in thousands) | 2025 |  | 2024 |  | $ |  | %
Income (loss) from equity method investments | $ | 5,412 |  |  | $ | 9,955 |  |  | $ | (4,543) |  |  | (46) | %
% of total revenues | — | % |  | 1 | % |  |  |  |

32

Table of Contents
Income (loss) from equity method investments decreased $4.5 million, or 46%, for the three months ended June 30, 2025 compared to the same period in 2024 primarily from increases in operating expenses during 2025 compared to 2024 from our CMS ACO Models investments.

| Six Months Ended June 30, |  | Change
(dollars in thousands) | 2025 |  | 2024 |  | $ |  | %
Income (loss) from equity method investments | $ | 18,084 |  |  | $ | 15,639 |  |  | $ | 2,445 |  |  | 16 | %
% of total revenues | 1 | % |  | 1 | % |  |  |  |

Income (loss) from equity method investments increased $2.4 million, or 16%, for the six months ended June 30, 2025 compared to the same period in 2024 primarily from the higher medical margin in 2025 from our CMS ACO Models investments.
Other income (expense), net

| Three Months Ended June 30, |  | Change
(dollars in thousands) | 2025 |  | 2024 |  | $ |  | %
Other income (expense), net | $ | 7,879 |  |  | $ | 4,841 |  |  | $ | 3,038 |  |  | 63 | %
% of total revenues | 1 | % |  | — | % |  |  |  |

Other income (expense), net increased $3.0 million, or 63%, for the three months ended June 30, 2025 compared to the same period in 2024 primarily from $4.3 million of income related to services rendered to our CMS ACO Models investments that was recognized in 2025.

| Six Months Ended June 30, |  | Change
(dollars in thousands) | 2025 |  | 2024 |  | $ |  | %
Other income (expense), net | $ | 17,140 |  |  | $ | 10,733 |  |  | $ | 6,407 |  |  | 60 | %
% of total revenues | 1 | % |  | — | % |  |  |  |

Other income (expense), net increased $6.4 million, or 60%, for the six months ended June 30, 2025 compared to the same period in 2024 primarily from $8.5 million of income related to services rendered to our CMS ACO Models investments that was recognized in 2025.
Total Discontinued Operations

| Six Months Ended June 30, |  | Change
(dollars in thousands) | 2025 |  | 2024 |  | $ |  | %
Total discontinued operations | $ | 14,000 |  |  | $ | (9,281) |  |  | $ | 23,281 |  |  | 251 | %
% of total revenues | — | % |  | — | % |  |  |  |

Total discontinued operations relates to the sale of our Hawaii operations in October 2023. Total discontinued operations for the six months ended June 30, 2025 relates to the release of a contingent obligation from our Hawaii operations compared to losses from discontinued operations for the six months ended June 30, 2024.
Non-GAAP Financial Measures
In addition to providing results that are determined in accordance with U.S. GAAP, we present medical margin and Adjusted EBITDA, which are non-GAAP financial measures.
33

Table of Contents
We define medical margin as medical services revenue after medical services expense is deducted. Medical services expense represents costs incurred for medical services provided to our members. As our platform matures over time, we expect medical margin to increase in absolute dollars. However, medical margin PMPM may vary as the percentage of new members brought onto our platform fluctuates. New membership added to the platform is typically dilutive to medical margin PMPM. We believe this metric provides insight into the economics of our capitation arrangements as it includes all medical services expense directly associated with our members’ care.
We define Adjusted EBITDA as net income (loss) adjusted to exclude: (i) income (loss) from discontinued operations, net of income taxes, (ii) interest expense, (iii) income tax expense (benefit), (iv) depreciation and amortization, (v) stock-based compensation expense, (vi) severance and related costs, and (vii) certain other items that are not considered by us in the evaluation of ongoing operating performance. We reflect our share of Adjusted EBITDA for equity method investments by applying our actual ownership percentage for the period to the applicable reconciling items on an entity-by-entity basis.
Gross profit (loss) is the most directly comparable U.S. GAAP measure to medical margin. Net income (loss) is the most directly comparable U.S. GAAP measure to Adjusted EBITDA.
We believe medical margin and Adjusted EBITDA help identify underlying trends in our business and facilitate evaluation of period-to-period operating performance of our operations by eliminating items that are variable in nature and not considered by us in the evaluation of ongoing operating performance, allowing comparison of our recurring core business operating results over multiple periods. We also believe medical margin and Adjusted EBITDA provide useful information about our operating results, enhance the overall understanding of our past performance and future prospects, and allow for greater transparency with respect to key metrics we use for financial and operational decision-making. We believe medical margin and Adjusted EBITDA or similarly titled non-GAAP measures are widely used by investors, securities analysts, ratings agencies, and other parties in evaluating companies in our industry as a measure of financial performance. Other companies may calculate medical margin and Adjusted EBITDA or similarly titled non-GAAP measures differently from the way we calculate these metrics. As a result, our presentation of medical margin and Adjusted EBITDA may not be comparable to similarly titled measures of other companies, limiting their usefulness as comparative measures.
Adjusted EBITDA is not considered a measure of financial performance under U.S. GAAP, and the items excluded therefrom are significant components in understanding and assessing our financial performance. Adjusted EBITDA has limitations as an analytical tool and should not be considered in isolation or as an alternative to such U.S. GAAP measures as net income (loss), cash flows provided by or used in operating, investing, or financing activities or other financial statement data presented in our consolidated financial statements as an indicator of financial performance or liquidity. Some of these limitations are:
•Adjusted EBITDA does not reflect changes in, or cash requirements for, working capital needs;
•Adjusted EBITDA does not reflect interest expense or the requirements necessary to service interest or principal payments on debt;
•Adjusted EBITDA does not reflect income tax expense (benefit) or the cash requirements to pay taxes;
•Adjusted EBITDA does not reflect historical cash expenditures or future requirements for capital expenditures or contractual commitments;
•Although depreciation and amortization charges are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for such replacements; and
•The expenses and other items that we exclude in our calculation of Adjusted EBITDA may differ from the expenses and other items, if any, that other companies may exclude from similarly titled non-GAAP financial measures.
34

Table of Contents
The following table sets forth a reconciliation of gross profit (loss) to medical margin using data derived from our condensed consolidated financial statements for the periods indicated (dollars in thousands):

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Gross profit (loss)(1) | $ | (52,427) |  |  | $ | 32,175 |  |  | $ | (1,705) |  |  | $ | 107,263 |
Other operating revenue | (2,943) |  |  | (3,179) |  |  | (5,846) |  |  | (6,338) |
Other medical expenses | 2,164 |  |  | 76,523 |  |  | 82,357 |  |  | 161,947 |
Medical margin | $ | (53,206) |  |  | $ | 105,519 |  |  | $ | 74,806 |  |  | $ | 262,872 |

___________________________________________
(1)Gross profit (loss) is defined as total revenues less medical services expense and other medical expenses.
The following table sets forth a reconciliation of net income (loss) to Adjusted EBITDA using data derived from our condensed consolidated financial statements for the periods indicated (dollars in thousands):

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Net income (loss) | $ | (104,370) |  |  | $ | (30,662) |  |  | $ | (92,258) |  |  | $ | (36,696) |
(Income) loss from discontinued operations, net of income taxes | — |  |  | — |  |  | (14,000) |  |  | 9,281 |
Interest expense | 1,572 |  |  | 1,697 |  |  | 3,087 |  |  | 2,981 |
Income tax expense (benefit) | 62 |  |  | 417 |  |  | 258 |  |  | 284 |
Depreciation and amortization | 7,319 |  |  | 5,907 |  |  | 14,195 |  |  | 11,751 |
Severance and related costs | 119 |  |  | 868 |  |  | 644 |  |  | 3,283 |
Stock-based compensation expense | 15,381 |  |  | 18,207 |  |  | 32,101 |  |  | 35,116 |
EBITDA adjustments related to equity method investments(1) | 4,366 |  |  | 1,404 |  |  | 11,209 |  |  | 5,306 |
Other(2) | (7,782) |  |  | (668) |  |  | (18,002) |  |  | (5,082) |
Adjusted EBITDA | $ | (83,333) |  |  | $ | (2,830) |  |  | $ | (62,766) |  |  | $ | 26,224 |

___________________________________________
(1)Includes elimination of certain administrative services provided by agilon health, inc. to equity method investments.
(2)Includes interest income, transaction-related costs and elimination of certain administrative services provided by agilon health, inc. to equity method investments.
Liquidity and Capital Resources
We have historically financed our operations primarily through funds generated from our capitation arrangements with payors, issuances of equity securities, and borrowings under credit agreements. We generally invest any excess cash in money market accounts, which are classified as cash equivalents, and marketable securities. Our investment strategies are designed to provide safety and preservation of capital, sufficient liquidity to meet the cash flow needs of our business operations, and attainment of a competitive return. As of June 30, 2025, we had cash and cash equivalents of $171.4 million and investments in marketable securities of $155.6 million.
We expect to continue to incur operating losses and generate negative cash flows from operations for the foreseeable future due to the investments we intend to continue to make in expanding our business and additional general and administrative costs we expect to incur related to our operation as a public company. As a result, we may require additional capital resources in the future to execute strategic initiatives to grow our business.
Our primary uses of cash include payments for medical claims and other medical expenses, general and administrative expenses, costs associated with the development of new geographies and expansion of existing geographies, debt service, and capital expenditures. Final reconciliation and receipt of amounts due from payors are typically settled in arrears, following completion of the contractual program year.
35

Table of Contents
Based on our planned operations, we believe that our existing cash and cash equivalents, investments in marketable securities, as well as available borrowing capacity under the Credit Facility (defined below), will be sufficient to meet our working capital and capital expenditure needs over at least the next 12 months, though we may require additional capital resources in the future. We have based these estimates on assumptions that may prove to be wrong and we could utilize our available capital resources sooner than we expect.
We may require additional financing in the future to fund working capital and pay our obligations. We may seek to raise any necessary additional capital through a combination of public or private equity offerings and/or debt financings. There can be no assurance that we will be successful in acquiring additional funding at levels sufficient to fund our operations or on terms favorable to us, if at all. If adequate funds are not available on acceptable terms when needed, we may be required to significantly reduce operating expenses, which may have a material adverse effect on our business, financial condition, cash flows, and results of operations. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends.
Our ability to pay dividends to holders of our common stock is significantly limited as a practical matter by our growth plans as well as the Credit Facility insofar as we may seek to pay dividends out of funds made available to us by agilon health management, inc. (“agilon management”) or its subsidiaries because the Credit Facility restricts agilon management’s ability to pay dividends or make loans to us. The borrower on the Credit Facility is agilon management, our wholly-owned subsidiary. The Credit Facility is guaranteed by certain of our subsidiaries, including those identified as variable interest entities, and contain customary covenants including, among other things, limitations on restricted payments including: (i) dividends and distributions from restricted subsidiaries, (ii) requirements of minimum financial ratios, and (iii) limitation on additional borrowings based on certain financial ratios.
Cash Flows
The following summary discussion of our cash flows is based on the condensed consolidated statements of cash flows. The following table sets forth changes in cash flows (dollars in thousands):

| Six Months Ended June 30,
| 2025 |  | 2024 |  | Change
Net cash provided by (used in) operating activities | $ | (67,072) |  |  | $ | (66,493) |  |  | $ | (579) |
Net cash provided by (used in) investing activities | 47,369 |  |  | 69,655 |  |  | (22,286) |
Net cash provided by (used in) financing activities | (2,741) |  |  | (1,155) |  |  | (1,586) |

Net Cash Provided By (Used In) Operating Activities
Net cash used in operating activities was $67.1 million for the six months ended June 30, 2025 compared to $66.5 million for the six months ended June 30, 2024. Net cash used in operating activities remained relatively flat. Our cash flow from operations is dependent upon the number of members on our platform, the timing of settlements with payors, and the level of operating and general and administrative expenses necessary to operate and grow our business, among other factors.
Net Cash Provided By (Used In) Investing Activities
Net cash provided by investing activities was $47.4 million for the six months ended June 30, 2025 compared to $69.7 million for the six months ended June 30, 2024. During the six months ended June 30, 2025, we received proceeds from the maturities of marketable securities of $125.3 million and made investments of $78.0 million primarily for marketable securities, and the acquisition of intangible assets and property and equipment. During the six months ended June 30, 2024, we received proceeds from the maturities of marketable securities of $115.7 million and made investments of $46.1 million primarily for marketable securities, and the acquisition of intangible assets and property and equipment.
36

Table of Contents
Net Cash Provided By (Used In) Financing Activities
Net cash used in financing activities was $2.7 million for the six months ended June 30, 2025, relating to equity issuances, compared to net cash used in financing activities of $1.2 million for the six months ended June 30, 2024, related to repayments of debt.
Debt Obligations
On February 18, 2021, we executed a credit facility agreement (as amended by the First Amendment to Credit Agreement, dated as of March 1, 2021 and the Second Amendment to Credit Agreement, dated as of May 25, 2023, the “Credit Facility”). The Credit Facility includes: (i) a $100.0 million senior secured term loan (the “Secured Term Loan Facility”) and (ii) a $100.0 million senior secured revolving credit facility (the “Secured Revolving Facility”) with a capacity to issue standby letters of credit in certain circumstances up to a maximum of $100.0 million. Subject to specified conditions and receipt of commitments, the Secured Term Loan Facility may be expanded (or a new term loan facility, revolving credit facility or letter of credit facility added) by up to (i) $50.0 million plus (ii) an additional amount determined in accordance with a formula tied to repayment of certain of our indebtedness. The maturity date of the Credit Facility is February 18, 2026.
Effective with the Second Amendment to Credit Agreement on May 25, 2023, we transitioned to the Secured Overnight Financing Rate (“SOFR”) as a benchmark interest rate used in the Credit Agreement. At our option, borrowings under the Credit Facility can be either: (i) SOFR Rate Loans, (ii) Daily Simple SOFR Rate Loans, or (iii) Base Rate Loans. Daily Simple SOFR Rate Loans and SOFR Rate Loans bear interest at a rate equal to the sum of 3.50% and the higher of (a) SOFR, as defined in the Credit Agreement, and (b) 0%. Base Rate Loans bear interest at a rate equal to the sum of 2.50% and the highest of: (a) 0.50% in excess of the overnight federal funds rate, (b) the prime rate established by the administrative agent from time to time, (c) the one-month SOFR rate (adjusted for maximum reserves) plus 1.00% and (d) 0%. Additionally, we pay a commitment fee on the unfunded Secured Revolving Facility amount of 0.375%. We must also pay customary letter of credit fees.
The Credit Facility contains customary covenants including, among other things, limitations on restricted payments including: (i) dividends and distributions from restricted subsidiaries, (ii) requirements of minimum financial ratios, and (iii) limitation on additional borrowings based on certain financial ratios.
For additional discussion on our debt obligations, see Note 8 to the Condensed Consolidated Financial Statements.
Equity
As of June 30, 2025, we had 414.3 million shares of common stock outstanding. See Note 10 to the Condensed Consolidated Financial Statements for additional information about our equity transactions.
Critical Accounting Estimates
Management’s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires us to use judgment in the application of accounting policies, including making estimates and assumptions. We base estimates on the best information available to us at the time, our historical experience, known trends and events, and various other assumptions that we believe are reasonable under the circumstances. These estimates affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. If our judgment or interpretation of the facts and circumstances relating to various transactions or other matters had been different, it is possible that different accounting would have been applied, resulting in a different presentation of our condensed consolidated financial statements. From time to time, we re-evaluate our estimates and assumptions. In the event estimates or assumptions prove to be different from actual results, adjustments are made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. A summary of our critical accounting policies is included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 in Part II, Item 7 “Management’s Discussion and Analysis of Financial Conditions and Results of Operations - Critical Accounting Policies” and Note 2 to the Condensed Consolidated Financial Statements. There have been no significant changes to our critical accounting policies during 2025.
37

Table of Contents
Recent Accounting Pronouncements
For the impact of new accounting standards, see Note 2 to the Condensed Consolidated Financial Statements.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
We are exposed to various market risks, including the potential loss arising from adverse changes in interest rates. We do not use derivative financial instruments in the normal course of business or for speculative or trading purposes.
Our exposures to market risk for changes in interest expense relate primarily to the Credit Facility. Indebtedness under the Credit Facility is floating rate debt and is carried at amortized cost. Therefore, fluctuations in interest rates will impact our consolidated financial statements. A rising interest rate environment will increase the amount of interest paid on this debt. A hypothetical 100 basis point change in interest rates would not have a material impact on our interest expense.
We held cash, cash equivalents, restricted cash and equivalents, and marketable securities of $327.0 million and $405.6 million as of June 30, 2025 and December 31, 2024, respectively, consisting of bank deposits, certificates of deposits, money market funds, U.S. Treasury notes, and corporate debt securities. Such interest-earning instruments carry a degree of interest rate risk. A hypothetical 100 basis point change in interest rates would not have a material impact on the fair value of our marketable securities. Declines in interest rates over time will reduce our investment income. The goals of our investment policy are liquidity and capital preservation. We do not enter into investments for trading or speculative purposes.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures. Our interim Principal Executive Officers (each a “PEO” and together, the “PEOs”), one of whom also serves as our Chief Financial Officer (“CFO”), with the assistance of other members of management, have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report. Based on that evaluation, our PEOs and our CFO have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective to provide reasonable assurance that the information we are required to disclose in the reports we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s (“SEC”) rules and forms and (2) accumulated and communicated to our management, including our PEOs and our CFO, as appropriate to allow timely decisions regarding required disclosure.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect every misstatement. An evaluation of effectiveness is subject to the risk that the controls may become inadequate because of changes in conditions, or that the degree of compliance with policies or procedures may decrease over time.
Changes in Internal Control Over Financial Reporting. Under applicable SEC rules (Exchange Act Rules 13a-15(d) and 15d-15(d)), management is required to evaluate any change in internal control over financial reporting that occurred during each fiscal quarter that had materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. There were no changes in our internal control over financial reporting that occurred during our most recently completed fiscal quarter ended June 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
38

Table of Contents
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
See the “Legal Proceedings” section of Note 9 to the Condensed Consolidated Financial Statements for information regarding legal proceedings, which information is incorporated by reference in this Item 1.
Item 1A. Risk Factors
In addition to the information set forth in this Form 10-Q, you should carefully consider the risk factors disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. There have been no material changes to the risk factors disclosed in the Form 10-K.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
(a)
Unregistered Sales of Equity Securities
Certain of our agreements with our physician partner entities provide for grants of time-vested restricted stock units and performance-based restricted stock units (collectively, RSUs) to the physician partner entities. On May 19, 2025, and June 16, 2025, we issued 80,091 and 14,401 shares of our common stock upon vesting of RSUs, respectively, to our physician partners for a total of $218,807. The issuances of the common stock were exempt from registration under the Securities Act by virtue of Section 4(a)(2) of the Securities Act. These transactions did not involve any public offering, any underwriters, any underwriting discounts or commissions, or any general solicitation or advertising. The shares of common stock issued are subject to appropriate restrictive legends and the physician partner entities represented they would not transfer or distribute the common stock until all restrictions were cleared. All recipients had access, through their relationships with us or otherwise, to adequate information about us.
(b)
None.
(c)
None.
Item 5. Other Information
During the three months ended June 30, 2025, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” (as such terms are defined in Item 408 of Regulation S-K under the Act).
39

Table of Contents
Item 6. Exhibits

Exhibit Number |  | Description
10.1† |  | Form of Employee Performance Restricted Stock Unit Agreement – Transformational Goal.†*
31.1 |  | Certification by Benjamin Shaker, agilon’s interim Principal Executive Officer, Pursuant to Securities Exchange Act Rule 13a-14(a).*
31.2 |  | Certification by Jeffrey Schwaneke, agilon’s Principal Financial Officer and interim Principal Executive Officer, Pursuant to Securities Exchange Act Rule 13a-14(a).*
32.1 |  | Certification by Benjamin Shaker, agilon’s interim Principal Executive Officer, Pursuant to Securities Exchange Act Rule 13a-14(b) and 18 U.S.C. Section 1350.**
32.2 |  | Certification by Jeffrey Schwaneke, agilon’s Principal Financial Officer and interim Principal Executive Officer, Pursuant to Securities Exchange Act Rule 13a-14(b) and 18 U.S.C. Section 1350.**
101.INS |  | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.*
101.SCH |  | Inline XBRL Taxonomy Extension Schema Document.*
101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document.*
101.DEF |  | Inline XBRL Taxonomy Extension Definition Linkbase Document.*
101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase Document.*
101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document.*
104 |  | Cover Page Interactive Data File (embedded within the Inline XBRL document).*

___________________________________________
*Filed herewith.
**Furnished herewith.
† Identifies each management contract or compensatory plan or arrangement.
40

Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: August 4, 2025 |  | agilon health, inc.
|  | (Registrant)
|  | /s/ JEFFREY SCHWANEKE
|  | Jeffrey Schwaneke
|  | Chief Financial Officer and Member of the Office of the Chairman
|  | (Principal Financial Officer and Interim Principal Executive Officer)

41